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Background:  Hot flashes and night sweats, or vasomotor symptoms (VMS), are reported by an 
estimated 70-80% of women during the menopausal transition.  Measures of negative affect are 
among the strongest and most consistent correlates of all aspects of VMS experience, though the 
mechanisms linking these factors are unclear.  The current study aimed to examine the within 
day and day-to-day relationships between vasomotor symptoms and negative affect, and the 
potential role of sleep disturbance and cortisol dysregulation in these relationships, in a sample 
of women in midlife.   
Methods:  Fifty-three women (49% African American) who reported daily vasomotor symptoms 
were enrolled in an ambulatory study.  For seven days, participants documented their mood state, 
VMS experience, sleep, and health behaviors multiple times a day using electronic diaries, and 
wore Actiwatches to capture additional data related to sleep parameters.  Participants also 
provided morning and bedtime saliva samples for salivary cortisol collection over three days 
during the observed period.  Hierarchical linear regression was used to examine relationships 
between VMS, negative affect, and related factors. 
Results:  Accounting for a number of health and demographic variables, women reported more 
negative affect on both the same day (β=1.46, p<.001 for VMS bother) and the day following 
(β=0.80, p=0.02 for night sweat severity, β=0.61, p=0.02 for night sweat bother) a more negative 
experience of vasomotor symptoms.  A flatter diurnal cortisol slope was related to hot flash 
severity (β=0.09, p=0.03) and bother (β=0.10, p<.01) as well as negative affect (β=0.68, p=0.01), 
and partially explained the relationship between negative affect and VMS.  Sleep disturbance did 
not appear to play a role in linking VMS to next day negative affect. 
Conclusion:  The subjective experience of VMS plays a key role in relationships between VMS, 
negative affect, and health-related factors on a daily basis.  The findings of this study do not 
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support a small role of sleep disturbance in linking night sweat severity to next day negative 
affect, but suggest that further research is warranted to better understand the relationship between 
daily VMS experience, stress physiology, and negative affect.    
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1.0  INTRODUCTION 
Hot flashes and night sweats, or vasomotor symptoms (VMS), are reported by an estimated 70-
80% of women during the menopausal transition (Gold et al., 2006). The frequency, duration, 
severity, and bothersomeness of VMS are highly variable, and explanatory mechanisms for these 
differences in experience are only partially understood. Measures of negative affect are among 
the strongest and most consistent correlates of all aspects of VMS experience (Woods, Mitchell, 
& Landis, 2005), though the mechanisms linking these factors are unclear.  Further, this 
relationship is typically explored in cross-sectional or longitudinal studies in which negative 
affect and VMS are retrospectively reported at one point in time, which contributes 
methodological concerns and provides no information about the daily experience of these 
variable symptoms.  While the current literature has established that negative affect and VMS are 
strongly associated when measured at one point in time, limitations in study design do not allow 
for an understanding of the daily experience of these variable symptoms, their temporal 
associations, or what mechanisms might explain these associations. 
A number of factors may explain the relationship between affect and VMS. Disrupted 
sleep in midlife is often attributed to VMS and posited to contribute to impaired next-day 
psychological functioning, as well as increased risk for depression over time.  However, this 
relationship is not always seen in research, particularly when using objective measures of sleep 
or VMS (Joffe et al., 2009).  Disrupted sleep may also contribute to dysregulation of diurnal 
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cortisol rhythms (Balbo, Leproult, & Van Cauter, 2010), which has been linked to depression 
and other measures of negative affect (Heaney, Phillips, & Carroll, 2010).  In addition to this 
indirect pathway, cortisol dysregulation may link VMS and negative affect more directly.  VMS, 
as a frequent, uncontrollable, often publicly embarrassing stressor, has been posited to increase 
cortisol levels as symptoms occur, contributing to cortisol dysregulation and changes in affect 
over time, particularly with frequent and/or severe VMS (Meldrum et al., 1984).  Cortisol 
dysregulation has been researched in the context of negative affect, but not well-studied in 
relation to VMS.   
This study aims to use ambulatory data collection to investigate the daily and day-to-day 
associations between negative affect and VMS, and to explore explanatory mechanisms linking 
these factors.  The following pages review the common presentation and etiology of VMS, and 
the current literature on cross-sectional and temporal associations between negative affect and 
VMS.  Potential explanatory mechanisms to be investigated are reviewed next, and the study 
design and analytic plan are then presented. 
1.1 BACKGROUND 
1.1.1 Vasomotor symptoms in midlife 
Vasomotor symptoms (VMS), commonly referred to as hot flashes and night sweats, are 
experienced as temporary sensations of intense heat accompanied by sweating and flushing 
(Thurston et al., 2009).  VMS are a common experience of the menopausal transition, reported 
by an estimated 70-80% of women. Prevalence increases with advanced menopausal stages, with 
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VMS most often occurring in the late perimenopause and early post-menopause (Gold et al., 
2006).  Despite the common occurrence of these symptoms, the pathophysiology leading to 
VMS is only partially understood.  Current evidence best supports a thermoregulatory theory of 
VMS etiology.  
 Core body temperature follows a tightly controlled circadian rhythm, with integrated 
processing in the hypothalamus, body, and peripheral vascular operating to maintain a 
homeostatic state in response to changes in the external and internal environment.  Sweating and 
blood flow are the primary mechanisms for regulating body temperature (Deecher & Dorries, 
2007). VMS, characterized by sweating and peripheral vasodilation, are considered rapid and 
dramatic heat dissipation responses, responding to signals indicating an increase in core body 
temperature.  Core body temperature may not be truly elevated prior to VMS, but VMS may 
result from a disruption or miscommunication in temperature signaling between the brain and 
peripheral vasculature.  A common hypothesis is that the normal homeostatic thermoregulatory 
range controlled by the hypothalamus is altered during the menopausal transition, resulting in a 
narrowed thermoneutral zone.  Within these tighter temperature constraints, even a small and 
typically insignificant elevation in core body temperature could trigger heat dissipation events 
such as VMS (Freedman, 2005).  Another possibility is that the peripheral vasculature may have 
reduced responsivity with aging or menopause, contributing to delayed and altered responses of 
the vasculature to temperature signaling from the hypothalamus and body.  Finally, hypothalamic 
neural functioning and neurochemical signaling related to thermoregulation (Deecher & Dorries, 
2007), possibly including central serotonergic, noradrenergic, opioid, adrenal, and autonomic 
systems (Thurston, Christie, & Matthews, 2010), may be affected during this period.   
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Fluctuating gonadal hormone levels during the perimenopause and declining estradiol in 
the postmenopause are thought to play a key role in disrupting central thermoregulatory 
processing.  Changing estrogen levels likely impact all of these possible routes, with regulatory 
effects on hypothalamic thermoregulation, effects on endothelial function in the vasculature, and 
influence on neurochemical release as well as neurotransmitter receptor gene expression and 
function for key neurotransmitters related to temperature signaling (Deecher & Dorries, 2007).  
The primary role of estrogens in the etiology of VMS is supported by the onset of VMS during 
the menopause and other periods of estrogen withdrawal, as well as the efficacy of exogenous 
estrogen administration in reducing or eliminating VMS.  However, VMS are not experienced by 
all women experiencing either gradual or sudden estrogen withdrawal (Freedman, 2005). 
Further, the frequency, duration, severity (Woods et al., 2005), and bothersomeness (Thurston et 
al., 2008) of VMS are highly variable among women.  The reasons for these individual 
differences in VMS are unclear, and cannot currently be explained by these hormonal or 
biological factors.  A number of demographic and psychosocial risk factors seem to be more 
consistently and strongly related to all aspects of VMS experience.  VMS are more common 
among women with lower socioeconomic status, smokers, and higher body mass index (BMI) 
(Thurston & Joffe, 2011), though associations between BMI and VMS occurrence may vary by 
age or menopausal stage (Thurston, Santoro, & Matthews, 2011).  Measures of negative affect 
are a consistently found correlate of self-reported VMS experience (Woods et al., 2005). 
1.1.2 Vasomotor symptoms and negative affect 
Depressive and anxiety symptoms and disorders are often reported during the menopausal 
transition (Joyce T. Bromberger & Kravitz, 2011), and most investigations suggest that the risk 
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for depression in midlife is more common among women with VMS than those without VMS 
(Joffe et al., 2009). Vulnerability to mood symptoms during the perimenopause has been 
attributed to frequent and bothersome VMS (Woods et al., 2005).  In a number of cross-sectional 
analyses of samples of women in midlife, self-reported VMS occurrence, frequency, severity, 
and bother have been associated with anxiety (Blümel et al., 2004; Cheng et al., 2008; Hunter, 
Gupta, Papitsch-Clark, & Sturdee, 2009; Li, Yu, Ma, Sun, & Yang, 2008; Seritan et al., 2010; 
Thurston et al., 2008, 2009), depressive symptoms (Blümel et al., 2004; Brown, Gallicchio, 
Flaws, & Tracy, 2009; Cheng et al., 2008; Hunter, Gupta, Papitsch-Clark, & Sturdee, 2009; Joffe 
et al., 2002; Li, Yu, Ma, Sun, & Yang, 2008; Seritan et al., 2010; Thurston et al., 2008, 2009), 
psychological distress (Joyce T. Bromberger et al., 2003; J. T. Bromberger et al., 2001; Ishizuka, 
Kudo, & Tango, 2008), and negative affect (Collins & Landgren, 1994; Thurston et al., 2008).  
Different aspects of VMS experience may be more or less related to mood symptoms; negative 
affect is a significant correlate of self-reported VMS bother even after adjusting for frequency 
(Thurston et al., 2008).  The results of some studies suggest that VMS may be more strongly 
related to mood symptoms than to clinically significant mood disorders (Bosworth et al., 2001; 
Elavsky & McAuley, 2009; Oztürk, Eraslan, Mete, & Ozşener, 2006; Schmidt, Haq, & Rubinow, 
2004), and that associations between negative affect and VMS may be strongest in 
perimenopausal women compared to symptomatic pre- or postemenopausal women (Cheng et 
al., 2008; Joffe et al., 2002; Seritan et al., 2010).  Overall, most studies support an association 
between measures of negative affect and aspects of VMS experience, though much remains to be 
clarified about this association.  
The nature of the association between negative affect and VMS are not well understood, 
largely due to limitations in the typical measurement of VMS in the literature.  In research, VMS 
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is usually assessed with retrospective recall, queried as the occurrence of symptoms in the past 
one, two, or four weeks.  This methodology introduces issues of inaccuracy, as reliability may be 
reduced after even brief delays in symptom recall.  In one investigation, recall of VMS frequency 
at the end of the day resulted in underestimated VMS reporting compared to prospective self-
reported and physiologically detected VMS throughout that same day (Fu, Matthews, & 
Thurston, 2014).  Retrospective recall of somatic symptoms is also known to be biased by mood 
at the time of reporting, further contributing to reporting inaccuracies as well as potentially 
creating or inflating the relationship seen between affect and self-reported VMS.   
The influence of negative affect on VMS perception and reporting is highlighted by 
studies comparing self-report of VMS with objective VMS, typically physiologically detected 
with sternal skin conductance.  The correlation between reported VMS and objective VMS 
occurrence is not high (Sievert, 2013), and associations between self-report VMS and negative 
affect are not always seen with objective VMS.  When both self-report and physiological VMS 
are measured, self-reported VMS not corroborated by physiological evidence seem to be more 
common among women with high levels of anxiety (Thurston, Blumenthal, Babyak, & 
Sherwood, 2005; Thurston, Hernandez, Del Rio, & De La Torre, 2011) and depressive symptoms 
(Thurston et al., 2005).  With these issues in mind, future research on associations between VMS 
and negative affect should limit retrospective recall methods, account for trait-like characteristics 
related to negative affectivity, and recognize the potential role of negative affect in influencing 
perception and reporting of self-reported VMS. 
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1.1.3 Temporal associations between vasomotor symptoms and negative affect 
An additional limitation of the current literature is an inability to establish the directionality of 
the association between VMS and negative affect.  Cross-sectional methods support a 
relationship between VMS and negative affect when both are measured at one point in time, but 
do not allow for examination of the temporal associations between these factors.  The commonly 
seen association between self-reported VMS and negative affect may be due to negative affect 
contributing to VMS reporting, or VMS leading to negative affect. Few studies have specifically 
tested these pathways.  Negative affect leading to VMS on a year-to-year basis has been explored 
in four large epidemiological samples of women in midlife.  In the Penn Ovarian Aging Study 
(POAS), an observational cohort study of over 400 women in midlife, both previous year anxiety 
and an increase in anxiety scores from the previous year predicted the initial onset of VMS, 
measured as any VMS in the previous month, during the menopausal transition (Freeman et al., 
2005).   In additional analyses of the POAS, the onset of depressive symptoms was more likely 
to precede the onset of any VMS among participants who had neither at baseline and developed 
both over the 10-year observed period (Freeman, Sammel, & Lin, 2009).  Depressive symptoms 
at baseline predicted the development of VMS over the following four years of observation 
(Freeman et al., 2001).  Depressive symptoms at baseline also predicted the onset of any self-
reported menopausal symptoms, including but not limited to VMS, occurring at any time over 
ten years of observation in a large community sample in France (Sabia, Fournier, Mesrine, 
Boutron-Ruault, & Clavel-Chapelon, 2008), and self-reported bothersome VMS in the past two 
weeks over nine years among the 438 participants in the Melbourne Women's Midlife Health 
Project (Guthrie, Dennerstein, Taffe, Lehert, & Burger, 2005).  Depressive and anxiety 
symptoms at baseline predicted both annually reported VMS occurrence and reporting VMS on 
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six or more days in the previous two weeks annually in the Study of Women’s Health across the 
Nation (Gold et al., 2006).  The alternate pathway of VMS leading to negative affect over time 
was also investigated in the Melbourne Women’s Midlife Health Project, which found that 
depressive symptoms in the final study visit were predicted from the number of bothersome 
menopausal symptoms, including but not limited to VMS, at baseline ten years previously 
(Guthrie et al., 2005). 
 While epidemiological studies can explore the relationship between mood symptoms and 
disorders and VMS onset over the course of years, they provide no information about the within-
day and day-to-day relationship between these variable factors among symptomatic women.  
Annually collected data is also limited by retrospective report of VMS, which may be inaccurate 
and/or biased by mood at the time of reporting.  In contrast to the summary measures of negative 
affect and VMS collected in epidemiological studies, ambulatory and daily diary data can be 
utilized to investigate the relatively acute effects of negative affect on VMS, and vice versa, with 
limited retrospective recall bias.  However, very few published studies have explored temporal 
associations between negative affect and VMS in this fashion.   
 Ambulatory measurement of self-reported and objectively measured VMS has supported 
a role of anxiety in predicting both types of VMS.  However, while a number of factors were 
associated with objective VMS, only anxiety predicted VMS reporting in this sample (Thurston, 
Hernandez, et al., 2011).  When both VMS and affect were measured in an ambulatory fashion, 
Thurston et al. (Thurston et al., 2005) found that self-reported VMS without corroborating 
physiological evidence were more likely to be reported in the minutes following increased 
frustration and decreased feelings of control.  In contrast, physiologically identified VMS were 
less likely to follow increases in negative affect, and more likely to follow increases in positive 
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affect (Thurston et al., 2005).  The alternate pathway, self-reported VMS leading to negative 
affect, is supported by the limited data available from two published diary studies investigating 
this relationship on a day-to-day basis.  Burleson et al. (Burleson, Todd, & Trevathan, 2010) 
collected daily diary ratings of self-reported VMS and mood items from 55 healthy women in 
midlife for 36 weeks.  Negative affect was measured as a mean composite score of daily ratings 
of mood symptoms (anxious, depressed, distressed, nervous, hostile, ashamed, guilty, and 
irritable), while VMS was categorized as any or no occurrence of VMS during each 24-hour 
period.  VMS predicted higher next-day negative affect, but only in women who did not have 
high levels of depressive symptoms, measured with the Center for Epidemiological Studies for 
Depression (CESD) scale, at baseline (Burleson et al., 2010). While the findings supported the 
theory that VMS precedes negative affect over short periods of time, the effect of VMS on acute 
mood states was only seen in women with low stable measures of negative affect.   
 Gibson et al. (Gibson, Thurston, Bromberger, Kamarck, & Matthews, 2011) investigated 
the daily and day-to-day relationship between negative affect and VMS using data from the 
Daily Hormone Study, a subsample of women in the menopausal transition from the Study of 
Women’s Health Across the Nation.  In this multiethnic sample of 625 women, participants 
completed a daily diary each night before bed for approximately 30 days.  Negative affect was 
measured as a mean composite variable of mood ratings (mood swings, feelings easily hurt, 
irritable, difficulty concentrating, forgetful, anxious, and blue/down), dichotomized to indicate 
the presence or absence of negative mood each day.  As in Burleson et al. (2010), VMS was 
reported as any or no occurrence of VMS during each 24-hour period.  In this analysis, higher 
average negative affect over the month of daily diary collection was associated with an increased 
risk of reporting VMS over the month, and higher negative affect was associated with reporting 
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VMS within each 24-hour period.  On a day-to-day basis, VMS was associated with next day 
negative affect, while no association was seen between negative affect and next day VMS 
(Gibson et al., 2011).  
 In summary, negative affect as a trigger of self-reported VMS that do not meet objective 
criteria was supported by Thurston et al. (Thurston et al., 2005).  Burleson et al. (Burleson et al., 
2010) and Gibson et al. (Gibson et al., 2011) support daily relationship of VMS leading to 
negative affect, but both were limited by simplistic measures of both negative affect and VMS, 
with global negative and positive affect determined from ad hoc measurement of mood 
retrospectively reported at the end of the day, and VMS limited to a retrospective report whether 
or not any VMS occurred each day.  No published study has adequately examined the day-to-day 
relationship between aspects of VMS experience, including frequency, severity, and bother of 
VMS, and independent aspects of negative affect.  Improved measurement of prospectively 
reported depressive and anxiety symptoms is warranted to better assess these relationships.  
Replication and improvement upon existing methods would lend further support to this temporal 
association, while also adding to our ability to investigate potential mechanisms linking VMS 
and negative affect (figure 1). 
1.2 MECHANISMS LINKING VASOMOTOR SYMPTOMS AND NEGATIVE 
AFFECT 
Associations have been seen between VMS and negative affect on the same and subsequent day 
(figure 2).  A number of factors may explain the temporal relationship between VMS and 
negative affect.  On a day-to-day basis, VMS is thought to disturb sleep, with sleep problems in 
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turn contributing to next day negative affect (figure 3).  VMS-related sleep disturbance may also 
contribute to biological disruption associated with negative affect, while VMS itself may serve as 
a stressor causing acute stress responses resulting in overall higher stress hormone exposure 
(figure 4) and, with frequent or severe VMS exposure, dysregulation of stress hormone rhythms, 
also leading to increased negative affect (figure 5).   
1.2.1 VMS-related sleep disturbance contributing to next day negative affect 
The prevalence of sleep problems increases with aging for both men and women, with a marked 
increase seen among women compared to men at midlife (Kravitz et al., 2011).  At that time, an 
estimated 30-60% of peri- and postmenopausal women report sleep disturbance (Kravitz et al., 
2008).  Sleep problems are most common among women in midlife who also report VMS, and 
sleep difficulty is consistently associated with self-reported VMS in SWAN and other samples 
(Blümel et al., 2004; Kravitz et al., 2008, 2011).  Disturbed sleep is known to be associated with 
mood disorders and symptoms, and contributes to impaired next-day psychological functioning 
(Balbo et al., 2010; Kumari et al., 2009).  The domino hypothesis posits that VMS disturbs sleep, 
leading to next-day psychological impairment and negative affect (figure 3).  The contribution of 
self-reported VMS to perceived sleep disturbance among women in midlife has been supported 
in a number of cross-sectional studies, and disturbed sleep is known to impact psychological 
functioning and next-day mood (Joffe et al., 2009). With frequent disturbance due to VMS, this 
cycle of chronic sleep disruption contributing to impaired daytime functioning and well-being 
could lead to the development of clinically significant depressive symptoms (Joffe et al., 2009). 
The directionality of this pathway has been supported by daily diary studies, in which self-
reported trouble sleeping in the intervening night played a small but significant role in explaining 
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the relationship between VMS and next-day negative affect (Burleson et al., 2010; Gibson et al., 
2011).  However, as VMS and sleep in these studies was only measured as retrospective self-
reported single items indicating any occurrence of VMS, and the presence or absence of any 
trouble sleeping (Gibson et al., 2011) or sleep problems (Burleson et al., 2010) in the previous 24 
hours, additional research with improved measurement of key factors is needed to better 
elucidate this relationship. 
 A significant contribution of VMS to sleep disruption and poor sleep quality is a 
necessary assumption of the domino hypothesis, but the relationship between sleep difficulties in 
the late perimenopause and postmenopause and self-reported VMS seen in cross-sectional 
research may instead reflect VMS effects on symptom perception and reporting.  More 
bothersome self-reported overnight VMS are associated with sleep problems (Thurston et al., 
2008) and reporting feeling less rested upon awakening (Thurston, Santoro, & Matthews, 2012).  
When physiological data and morning self-reports are compared, women reporting poorer sleep 
have been shown to overestimate overnight VMS the following morning (Fu et al., 2014). 
Further, an association between VMS and sleep is not always seen when sleep or VMS are 
assessed with objective measures rather than self-report (Thurston, Santoro, & Matthews, 2012). 
Women with frequent nocturnal arousals may attribute awakenings to VMS, regardless of 
whether the sleep disturbance was truly related to VMS occurrence (Thurston, 2006); women 
with VMS may report poor sleep, regardless of whether sleep disturbance seems to truly occur.  
No difference between total sleep time, awakenings, and brief arousals measured by EEG in 
women with and without skin conductance-measured VMS was seen in one study of 31 women 
in midlife; further, sleep arousals occurring within two minutes of a flash in symptomatic women 
were no more likely to occur after VMS than before (Freedman, 2004).  In another study of 41 
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women with VMS, self-reported overnight VMS were not significantly associated with overnight 
VMS physiologically detected with skin conductance, and self-reported sleep complaints, 
depression, and anxiety were associated only with the self-reported VMS, but not with the 
physiologically detected VMS (Thurston, Blumenthal, Babyak, & Sherwood, 2006).  In a 
subsample of 52 women from the Study of Women’s Health across the Nation, while more self-
reported VMS recalled upon awakening are associated with lower sleep efficiency and higher 
WASO as measured by actigraphy, physiologically measured VMS over the same night was not 
related to those sleep parameters (Thurston et al., 2012).  Overall, these findings suggest that 
while women report sleep disturbance due to VMS, it is not clear that VMS is actually disturbing 
sleep in symptomatic women, or contributing to mood symptoms through this pathway.  
 Alternatively, objective measurement of sleep may not capture differences in nocturnal 
arousal that explain disparities between objective and subjective reports of sleep disturbance and 
poor sleep quality.  While menopausal status or VMS frequency did not predict differences in 
polysomnography measures of sleep disturbance, including total sleep time and percent of time 
in each sleep stage, from 370 pre-, peri-, and postmenopausal participants in the SWAN Sleep 
Study, EEG data suggests that women in late perimenopause and postmenopause have a higher 
beta arousal level, commonly elevated in insomnia, during sleep. This may explain the subjective 
reporting of poorer quality and more disturbed sleep, despite no differences seen in PSG 
measures, predicted by both menopausal stage and self-reported VMS frequency in this sample 
(Campbell et al., 2011).  Other studies have shown that patterns of sleep disturbance may differ 
over the course of the night, which may not be seen with traditional analytic approaches to 
objective sleep measurement.  In a small sample of 36 women, Freedman et al. (Freedman & 
Roehrs, 2006) found that polysomnography-measured brief sleep arousals and awakenings were 
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more common in women with VMS than those without during the first half of the night, with 
VMS detected by skin conductance typically preceding arousal.  This was not seen in the second 
half of the night, when REM sleep is more common and may be suppressing thermoregulatory 
response and subsequent VMS in symptomatic women (Freedman, 2006).  Additionally, the 
subjective experience of VMS may play a role in the discrepancies found between self-reported 
and objectively measured VMS and sleep disturbance.  Self-reported VMS severity was related 
to actigraphy-derived measures of sleep disturbance in a sample of 217 healthy postmenopausal 
women (Ensrud et al., 2009).  Bothersome VMS, though not self-reported VMS occurrence or 
frequency, were associated with self-reported sleep disturbance in a sample of 623 women in 
midlife (Xu et al., 2012).   
While evidence is mixed, and clouded by a number of methodological differences, ample 
evidence suggests that sleep may be affected by VMS perceived to be severe or bothersome, and 
that sleep disturbance contributes both acutely and cumulatively to negative affect.  Further study 
is needed to clarify the relationship between self-reported VMS and objective measures of sleep 
disturbance, and whether VMS contributes to negative affect through detrimental effects on sleep 
parameters. Data collection over repeated days with self-reported and objectively measured sleep 
parameters and improved VMS reporting, including assessment of VMS bother and severity, is 
needed to adequately examine the relationship between subjectively reported VMS and sleep, as 
well as the potential role of sleep disturbance in explaining the relationship between VMS and 
negative affect on a day-to-day basis. 
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1.2.2 VMS-related cortisol dysregulation contributing to negative affect 
Night sweats and hot flashes are often considered interchangeably, with reported values of each 
combined or hot flashes considered a proxy for night sweats.  However, differences between 
night sweats and hot flashes, and differences in their associations with related factors such as 
negative affect, are not clear. While night sweats may disturb sleep, contributing to next day 
negative affect, hot flashes during the day may contribute to negative affect through differential 
pathways.  One potential pathway is through hypothalamic pituitary adrenal (HPA) axis 
dysregulation, which is commonly studied in relation to depression and mood symptoms. If 
VMS contributes to stress-related cortisol overexposure and dysregulation (figure 4), this could 
be an additional pathway through which VMS contributes to negative affect (figure 5). 
HPA axis dysregulation is often assessed in research by measuring urinary, plasma, or salivary 
cortisol.  More recently, using hair samples to assay overall cortisol exposure over the past 
several months have also been utilized to assess HPA axis dysregulation and correlated health 
risks (Manenschijn et al., 2013).  Cortisol typically follows a pattern in which levels peak in the 
early morning and decline steadily across the day, creating a diurnal slope.  Levels also increase 
in response to stressors, particularly those involving socio-evaluative threat (Dickerson, Mycek, 
& Zaldivar, 2008).  Alterations in these expected patterns are thought to indicate dysregulation, 
and have been associated with mood symptoms and disorders (Heaney et al., 2010) as well as 
sleep problems (Kumari et al., 2009).  Depressive pathophysiology may result from persistent 
neurobiological changes related to hypercortisolemia (Palazidou, 2012), while disrupted sleep in 
turn impacts HPA axis activity, including increased cortisol stress reactivity (Hori et al., 2011), 
higher next-day cortisol levels (Buckley & Schatzberg, 2005, p. 200), and increased corticotropin 
releasing hormone and cortisol release nocturnal awakening, such as those possibly related to 
 16 
VMS (Balbo et al., 2010).  While a number of studies have linked parameters related to HPA 
axis dysregulation, most consistently diurnal slope (Heaney et al., 2010) with negative affect and 
sleep, a relationship between cortisol measures and VMS have been frequently suggested but not 
yet established. 
HPA axis dysregulation may contribute to the etiology of VMS, as the HPA and 
hypothalamic pituitary ovarian (HPO) axis are tightly integrated (Woods, Carr, Tao, Taylor, & 
Mitchell, 2006), and menopause-related changes in gonadal hormone cyclity are likely to 
influence HPA function and feedback sensitivity, with the fluctuating and declining levels of 
estrogen in the peri- and postmenopause leading to a decreased regulation and increased 
expression of HPA axis activity.  Age- and menopause-related increases in HPA axis activity 
may in turn further suppress HPO, affecting gonadal hormone secretion and hormonal influence 
on thermoregulation (Neal-Perry, Nejat, & Dicken, 2010).   While dysregulation of the 
integration of these axes with aging and menopause is likely, these pathways are difficult to 
examine and disentangle in observational research.  It has also been established that whatever the 
cause, changes in gonadal hormones and their potential influence on thermoregulation does not 
explain all of the variability in the occurrence or experience of VMS (Freedman, 2005).  
Alternatively, it has been posited that VMS may instead contribute to HPA axis dysregulation.   
 As an unpredictable and often socially embarrassing stressor (Smith, Mann, Mirza, & 
Hunter, 2011), VMS may trigger stress-related cortisol release and higher overall cortisol 
exposure across the day (Meldrum et al., 1984) (figure 4). VMS, particularly VMS reported as 
severe or bothersome, could therefore result in higher overall cortisol exposure and dysregulation 
of diurnal cortisol rhythms (Woods et al., 2006), in turn associated with increased negative 
affect.  Data from several studies of very small samples suggest that mean serum cortisol 
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concentration increases 15 minutes after VMS, supporting an acute stress response to VMS 
among symptomatic women (Cignarelli et al., 1989; Genazzani et al., 1984; Meldrum et al., 
1984).  In a subsample of the Seattle Midlife Women’s Health Study, overnight urinary cortisol 
levels were found to increase during the late perimenopause, and this increase was predicted by 
VMS severity (Woods et al., 2006).  However, in another analysis of the same sample spanning 
the entire menopausal transition, VMS the same day or day following overnight urinary cortisol 
collection were slightly associated with lower cortisol levels (Woods, Mitchell, & Smith-Dijulio, 
2009).  In a study of 85 healthy, early postmenopausal women, higher scores on the Greene 
Climacteric Scale, a questionnaire quantifying mood and somatic symptoms related to the 
menopausal transition, was significantly associated with higher 24-hour urinary cortisol levels.  
The VMS subscale alone was not associated with cortisol levels, though with only two questions 
may not be a reliable measure of VMS experience (Cagnacci et al., 2011).  In a study using 
salivary diurnal cortisol in 130 midlife women, no association was seen between self-reported 
VMS occurrence in the previous two weeks and diurnal cortisol patterns from one day of 
observation (Sievert, 2012).  Finally, in a study using applied relaxation to treat VMS, both VMS 
frequency and salivary cortisol was lower among women who received the applied relaxation 
intervention (n=33) compared to controls (n=27) three months following the end of the 
intervention (Lindh-Åstrand & Nedstrand, 2013).   
 Though mixed, current findings overall generally support an association between 
increased cortisol exposure and VMS, potentially as a result of stress-related cortisol increase 
subsequent to VMS.  However, interpretability of this small literature is limited by 
methodological concerns, including the small sample sizes (Cignarelli et al., 1989; Genazzani et 
al., 1984; Meldrum et al., 1984), use of overnight (Woods et al., 2006, 2009) and 24 hour urinary 
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cortisol (Cagnacci et al., 2011) to characterize typical cortisol exposure, and limited or 
retrospective measurement of VMS (Cagnacci et al., 2011; Sievert, 2012).  Diurnal salivary 
cortisol sampling has long been recognized as the best measure of cortisol exposure (Kirschbaum 
& Hellhammer, 1989), and hair cortisol sampling has recently become recognized as a clinically 
useful and valid measure of longer-term cortisol exposure (Russell, Koren, Rieder, & Van Uum, 
2012).  To date, no published data has used these techniques to examine relationships between 
cortisol and prospectively reported VMS. Further, HPA axis dysregulation as part of a 
mechanistic pathway linking VMS and negative affect in a sample with measurement of cortisol, 
VMS, and negative affect has not yet been examined.  Additional research is needed to establish 
the relationship between self-reported VMS and cortisol, and whether VMS may contribute to 
negative affect through changes in cortisol exposure.  The complementary use of mulitiple days 
of salivary diurnal cortisol collection and hair cortisol analysis, related with improved VMS 
reporting, including assessment of VMS bother and severity, and improved measurement of 
negative affect, is needed to adequately examine the relationship between self-reported VMS and 
cortisol. These methodological improvements will also help inform the potential role of cortisol 
in explaining the relationship between VMS and negative affect on an overall and day-to-day 
basis. 
1.3 SUMMARY 
A relationship between VMS and negative affect is consistently seen in the literature, though the 
relationship between variable aspects of both symptom and mood experience in daily life have 
not been well-established.  Though there is some evidence to suggest that VMS contribute to 
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negative affect, the mechanisms that underlie these associations are not well understood.  Sleep 
problems are commonly reported among women in midlife, and often attributed to VMS.  Sleep 
disturbance as a result of VMS may impair next-day psychological functioning and, over time, 
contribute to depression risk.  However, while a role of VMS in interrupting sleep is often seen 
in cross-sectional studies with self-reported sleep and VMS, the results are less consistent when 
sleep and/or VMS are assessed with objective measures.  The relationship between objective 
sleep measures, negative affect, and VMS has not been assessed in an ambulatory study where 
temporal associations between all can be assessed over time.  
Additionally, disturbed sleep may contribute to dysregulation of biological mechanisms 
linked to negative affect, including HPA axis functioning and cortisol exposure.  The experience 
of VMS as a chronic, unpredictable, socially relevant stressor may cause frequent stress cortisol 
responses to VMS, further contributing to cortisol dysregulation and providing another link 
between VMS and negative affect.  It is therefore proposed that VMS will predict same day and 
next-day negative affect, with sleep disturbance playing a role between severe and bothersome 
night sweats and next day negative affect, and diurnal cortisol exposure influenced by both sleep 
disruption and severe VMS, and contributing to the association between VMS and same-day and 
overall negative affect.  Though complex and bidirectional associations between VMS, sleep, 
cortisol, and negative affect are likely, the unidirectional pathways presented here were chosen 
as those most supported by the current literature, best integrating both sleep and cortisol as 
mechanisms linking VMS and negative affect, and testable by the proposed study. 
 For my dissertation study, I aimed to address the limitations of the current literature by 
using ambulatory methods to fully characterize and relate daily VMS and mood experiences of 
women across a typical week.  I used objective methods to assess the role of sleep disturbance, 
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diurnal cortisol dysregulation, and longer-term cortisol exposure as mediators that may better 
explain the relationship between VMS and negative affect.  Detailed assessment of daily VMS 
symptom experience, measurement of both depressive and anxiety symptoms, and stringent 
assessment of potential factors linking these common aspects of the menopausal transition was 
utilized to improve our understanding of the acute and cumulative contributions of VMS to 
aspects of negative affect among symptomatic women in midlife.   
1.4 SPECIFIC AIMS AND HYPOTHESES 
1.4.1 Specific Aim 1:  Examine the contribution of VMS to within-day and next-day 
negative affect. 
Hypothesis: VMS and negative affect will be associated on the same day, and VMS will predict 
next day negative affect (figure 1). These associations will be strongest with severe or 
bothersome VMS, consistent with the literature and the greater impact of severe and bothersome 
VMS on the health behaviors and physiological parameters proposed to link VMS and affect. 
 
1.4.2 Specific Aim 2:  Examine sleep as a mediator of the association between VMS and 
next-day negative affect. 
Hypothesis: Actigraphy-determined sleep efficiency and wake after sleep onset will partially 
explain the relationship between VMS and next day negative affect (figure 2).  Severe and/or 
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bothersome VMS in particular may disrupt sleep and contribute to arousal, awakening, and 
poorer sleep quality, impairing next-day psychological functioning. 
1.4.3 Specific Aim 3:  Examine cortisol as a correlate of VMS, negative affect, and sleep 
(a), and as a mediator of the association between VMS and negative affect (b). 
Hypothesis: VMS, along with sleep and negative affect, will be associated with a flatter diurnal 
cortisol slope (figure 3) and higher overall hair cortisol exposure. VMS, particularly severe 
VMS, may contribute acutely to cortisol stress reactivity and, with frequent occurrence, diurnal 
cortisol dysregulation contributing to long-term cortisol overexposure.  Sleep disruption is 
thought to contribute to increased cortisol secretion, autonomic activation, and corticotropin-
releasing hormone release, contributing to circadian cortisol dysregulation, while neurobiological 
changes related to stress-related HPA axis overactivation and cortisol overexposure contributes 
to the development of depressive symptoms and disorders.  Given these expected associations 
and pathways, cortisol exposure will also partially mediate the relationship between VMS and 
same day and overall negative affect (figure 4). 
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2.0  METHODS 
2.1 DESCRIPTION 
Participants were enrolled in a weeklong ambulatory study focused on VMS and negative affect.  
Following a telephone screen to determine eligibility and gather basic information, they 
completed an office visit consisting of informed consent and questionnaires.  They were then 
sent home with handheld electronic diaries (Palm, Inc., Santa Clara, CA) equipped with pre-
installed diary forms (Satellite Forms, Thacker Network Technologies, Inc.), an Actigraph, 
equipment to collect six samples of salivary cortisol, and written instructions for all study 
materials.  During the ambulatory portion of the study protocol, they completed self-initiated 
diary entries upon wakening and before bed, and signaled diary entries at four additional 
timepoints throughout each day.  They also completed salivary cortisol collection upon 
awakening and at bedtime on three consecutive weekdays during the data collection period.  
Upon completion, participants returned all equipment to the office in a prescheduled visit, where 
they also received compensation and were debriefed on the study. Participants were paid $50 for 
participation, split between completion of the laboratory portion ($10), ambulatory monitoring 
($30), and cortisol collection ($10).  Salivary cortisol collection days were scheduled for each 
individual such that they occurred on three consecutive weekdays, with efforts made to ensure 
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that VMS, mood, and sleep data collection occurred on at least one day/night prior to and 
following salivary cortisol collection. 
2.2 SAMPLE 
Fifty-three women from the community were enrolled in this study.  Recruitment efforts 
included advertisements in the UPMC Extra, flyers in public spaces around the city and doctors’ 
offices, and the University of Pittsburgh Clinical and Translational Science Institute’s Research 
Participant Registry.  Eligible participants were peri- or postmenopausal women who self-
reported daily VMS.  Women reporting current (within the past 3 months) use of oral 
contraceptives, hormone therapy, tamoxifen, aromatase inhibitors, SSRIs, SNRIs, lithium, 
antipsychotic medication, prescription sleep aids, corticosteroids, and any diagnosed primary 
sleep disorders were excluded from participation due to the known effects of these treatments 
and conditions on VMS, mood, sleep, and/or systemic cortisol levels. 
2.3 MEASUREMENT 
2.3.1 Telephone screen 
Potential participants completed a telephone screen to determine eligibility.  In addition to 
information about the inclusion/exclusion criteria, the screen queried demographic and 
menopause-related information with known associations with both VMS and negative affect, 
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including birth date and current age, race/ethnicity, highest level of educational attainment, self-
rated health (“In general, would you say your health is excellent, very good, good, fair or 
poor?”), menopausal status based on self-reported bleeding patterns (early perimenopausal 
(bleeding in the last 3 months with some change in cycle regularity in the last 12 months), late 
perimenopausal (bleeding >3 months ago but within the last 12 months), postmenopausal (no 
bleeding in the last 12 months), smoking status (current yes/no, past yes/no), age, and vasomotor 
symptom experience (past two weeks frequency, typical severity (mild:  sensation of heat 
without sweating; moderate:  sensation of heat with sweating, able to continue activity; severe:  
sensation of heat with sweating, causing cessation of activity) (Guttuso, DiGrazio, & Reddy, 
2012), typical bother (not at all, very little, moderately, a lot); lifetime duration) (Thurston et al., 
2008).  Participants were also be asked about current over the counter and prescription 
medication use, including oral contraceptives and hormone therapies, which may influence 
menopausal symptoms and diurnal cortisol patterns.  The telephone script and all data captured 
during screening were entered through RedCap, a password-protected, encrypted, secured 
database administered by the University of Pittsburgh. 
2.3.2 Office visit 
Participants came to the research office for a scheduled 1-2 hour visit, during which time they 
reviewed and signed IRB-approved informed consent documents, received instructions on study 
equipment, and completed the following measures and tasks: 
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2.3.2.1 Questionnaires 
 
Participants completed computer-based questionnaires using RedCap to assess a number of state 
and trait measures of psychological factors and health behaviors.  Relatively stable traits related 
to anxiety were measured with the Anxiety Sensitivity Index (Taylor et al., 2007) and the 
Spielberger Trait Anxiety Scale (Spielberger, Gorsuch, R.L., Lushene, R., Vagg, P.R., & Jacobs, 
G.A., 1983).  The Center for Epidemiological Studies Depression Scale (Radloff, 1977) was 
completed to assess depressive symptoms over the previous two weeks. The Mini-IPIP 
(Donnellan, Oswald, Baird, & Lucas, 2006), a 20-item short form of the 50-item International 
Personality Item Pool-Five-Factor Model measure (Goldberg, 1999), was used to assess 
personality measures consistent with the Big Five.  Neuroticism was the trait personality measure 
of primary interest, given known associations between neuroticism and somatic symptom 
reporting (Feldman, Cohen, Doyle, Skoner, & Gwaltney, 1999) and a more stressful perception 
of the menopausal transition (Elavsky & McAuley, 2009).   These longer-term measures were 
used to compare reported negative affect during the observed period to “typical” affectivity for 
each participant, and to test for moderation of relationships of transient mood states and VMS by 
more stable negative affect.  Attitudes Toward Aging and Menopause (Sommer et al., 1999) 
were assessed, given known associations between these attitudes and both VMS and depressive 
symptoms among women in midlife (Ayers, Forshaw, & Hunter, 2010). Typical self-reported 
sleep was assessed using the Pittsburgh Sleep Quality Index (Buysse, Reynolds, Monk, Berman, 
& Kupfer, 1989), in order to compare self-reported sleep measures to those objectively measured 
by actigraphy during the study.  Typical physical activity, a health behavior that may influence 
both mood and VMS, was assessed with the International Physical Activity Questionnaire Short 
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Form (Craig et al., 2003). Finally, the Hot Flash Related Daily Interference Scale (Carpenter, 
2001) was completed as an additional measure of the self-reported typical burden of VMS.  
Completion of these questionnaires took approximately 20-45 minutes, with most variability in 
duration due to the participants’ varying levels of familiarity and comfort with using a computer. 
2.3.2.2 Physical measures 
 
BMI and waist circumference were obtained during the initial study visit, due to known 
associations between these measures and both negative affect and VMS.  Trained staff measured 
participants’ height and weight using a laboratory stadiometer (BMI was calculated from weight 
(kg) and height (m)
2 
), and waist circumference using a laboratory measuring tape.  Waist 
circumference was measured in centimeters with a measuring tape placed around the participant 
at the narrowest part of the torso. 
2.3.2.3 Hair cortisol 
 
A sample of hair for cortisol analysis was obtained by trained study staff, cut from close to the 
scalp.  Due to the increased likelihood of participant concern or discomfort about providing this 
sample, participants were given the option to refuse this portion of the protocol without 
withdrawing from the study.  Providing a hair sample for cortisol analysis was not included in 
the criteria for receiving full payment for study participation. 
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2.3.3 Ambulatory monitoring 
Following the laboratory visit, participants completed seven days of ambulatory monitoring. 
2.3.3.1 Electronic daily diaries 
 
Participants were given handheld Palm Pilots (Palm, Inc., Santa Clara, CA) with pre-installed 
diary forms (Satellite Forms, Thacker Network Technologies, Inc.) that they completed upon 
wakening, before bed, and at four additional times over the course of each day upon signaling 
from pre-programmed alarms (Appendix B).  During the office visit, participants were trained on 
how to use the diary.  While participants were reminded of the importance of responding to the 
alarm as soon after it sounds as possible, they were shown how to delay response when in 
situations that make responding immediately dangerous or difficult.   
(a) Signalled within-day entries 
 
Participants were signaled by their electronic diaries to complete a diary entry four times evenly 
spaced throughout the day, at 11 am, 2 pm, 5 pm, and 8 pm.  While it was expected that sleep 
and wake times would be significantly variable between participants, and possibly within 
participants over the course of the observed period, these times were selected to maximize 
adherence (consistent signal times throughout the week, during times unlikely to coincide with 
meals or other obligations) and comparability between participants.  Within-day entries briefly 
collected information on VMS and affect.   
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(i) Vasomotor symptom reporting 
 
Participants were prompted to report the number of VMS experienced since the last report, as 
well as the peak severity and peak bother of VMS during that time.  VMS severity categorization 
(1/mild:  sensation of heat without sweating; 2/moderate:  sensation of heat with sweating, able 
to continue activity; 3/severe:  sensation of heat with sweating, causing cessation of activity) 
followed the FDA guidelines for defining VMS severity (Guttuso et al., 2012), while 
categorization of VMS bother (1/not at all, 2/very little, 3/moderately, 4/a lot) is consistent with 
measures in the literature (Thurston et al., 2008).  Participants were also asked to report the 
approximate time of their last VMS. 
(ii) Mood reporting 
 
Participants were prompted to report the extent to which they were currently experiencing 
symptoms of positive or negative affect and anxiety, using prompts from the PANAS-X 
(Negative Affect Scale (afraid, scared, nervous, jittery, irritable, hostile, guilty, ashamed, upset, 
distressed), Positive Affect Scale (active, alert, attentive, determined, enthusiastic, excited, 
inspired, interested, proud, strong), and Sadness Subscale (sad, blue, downhearted, alone, lonely) 
(Watson & Clark, 1994). In order to enable a comparison of negative affect in this study from 
that of Gibson et al.(Gibson et al., 2011), additional ad hoc items (moody, sensitive, and 
forgetful) were also included in the response forms.  All individual items were rated on a likert 
scale (1: very slightly or not at all, 2:  a little, 3:  moderately, 4:  quite a bit, 5:  extremely), 
consistent with recommended use of the PANAS (Watson & Clark, 1994) and typical use in 
ecological momentary assessment (Steptoe, Gibson, Hamer, & Wardle, 2007).   
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(iii) Contextual factors 
To aid in interpreting mood states at the time of reporting, signaled diaries also queried 
participants about their external and interpersonal environment.  These questions were, “Are you 
alone?” (yes/no) and “Where are you?” (1/work, 2/home, 3/in public).  Each diary entry took 
approximately 5-7 minutes to complete.   
(b) Self-initiated morning entry 
 
Morning diary entries were completed upon awakening, designed to capture information on what 
time participants woke up, what time they got into bed, what time they think they fell asleep the 
night before, the prior night’s sleep quality (including trouble sleeping, yes/no, for comparability 
with Gibson et al. (Gibson et al., 2011) and Burleson et al. (Burleson et al., 2010)), and the 
number, severity, and bother of any vasomotor symptoms experienced overnight. 
(c) Self-initiated end-of-day entry 
 
Bedtime diary entries were completed each night before sleep, designed to capture information 
on the time they went to bed, their mood at the time of entry, vasomotor symptoms (frequency, 
severity, bother) since the last entry, exercise (yes/no, time of day), alcohol use (yes/no, time of 
day of last use), tobacco use (yes/no, time of day of last use), and any naps (number, 
approximate time of day of all naps) experienced over the course of the day.  Affect and VMS 
questions were equivalent to those collected throughout the day, so that this data could be 
included as a fifth timepoint in the day.  
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2.3.3.2 Actigraphy 
 
Sleep was also assessed using actigraphy, with participants wearing Actiwatches throughout the 
observed period.  Target sleep parameters included sleep duration, sleep efficiency, and wake 
after sleep onset.  Actigraphy has been well-validated for the measurement of these parameters 
(Martin & Hakim, 2011), which relate to the sleep disruption thought to characterize the negative 
impact of VMS on sleep.  Participants were also asked to press the event marker button on their 
Actiwatch each time they experienced vasomotor symptoms.   
2.3.3.3 Salivary cortisol collection 
 
At the office visit, participants were given six Salivette collection devices (Sarstedt, Numbrecht, 
Germany), cotton/polyester swabs in individual tubes that are commonly used for salivary 
cortisol collection, and instructed to collect six samples over three consecutive days.  Participants 
were instructed to conduct salivary cortisol collection upon awakening and at bedtime (Adam & 
Kumari, 2009; Lederbogen et al., 2010).  Participants were encouraged to keep the saliva kit next 
to their bed along with a pen to record collection times on the sample tubes (Halpern, Whitsel, 
Wagner, & Harris, 2012).  Participants were instructed that “wake” time for the initial collection 
should mean, “When you open your eyes and are aware of being awake for the day, but before 
your feet touch the ground.”  Actigraphy wake times were compared to the time of data 
collection indicated for the initial sample collection to determine accuracy (Adam & Kumari, 
2009).  Participants were instructed on the timeline and procedure for collection during their 
laboratory visit.  Participants were instructed to refrain from eating, smoking, or consuming 
alcohol for one hour prior to collection, and to chew on the swabs for at least 30 seconds before 
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transferring it back to the tube, which they then marked with their initials, date, and time of 
collection, and placed in their home refrigerators until their scheduled date to return supplies to 
the laboratory.  In order to maintain stability of samples, salivary cortisol can be kept at 4–8 °C 
in household refrigerators for up to 7 days, and stored at 5 °C for up to 3 months or at -20  -80 °C 
for up to 12 months (Inder, Dimeski, & Russell, 2012). 
2.4 DATA REDUCTION AND MANAGEMENT 
2.4.1 Actigraphy 
An Actiwatch-16 (Philips Respironics, Inc.) was worn on participants’ non-dominant wrist 
continuously for 7 days and nights, with data stored in 1-minute epochs for the duration of the 
observed period.  Sleep time was determined by participants’ diary-reported time to bed and time 
awake, verified by representative changes in actigraphy.  Validated software algorithms 
(Actiware Version 5.04) was used to estimate sleep efficiency and wake after sleep onset within 
the designated sleep intervals. Nightly values for each participant and an average value for each 
participant across the 7 nights of observation was also calculated and maintained in the dataset 
for analysis.  Sleep efficiency, or the percentage of time in bed that is spent sleeping, was 
calculated as time spent asleep/time in bed × 100. Wake after sleep onset (WASO) was 
calculated as the total minutes of wakefulness between diary-reported sleep onset and final wake 
time.  Awakenings were defined as a total activity count greater than a sensitivity threshold of 
40. 
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2.4.2 Cortisol 
Salivary and hair cortisol samples were sent to Dresden Lab Services in Dresden, Germany for 
processing, under the direction of Clemens Kirschbaum, PhD.  Distributions of salivary cortisol 
data were examined for normality and outliers, and log-transformed to normalize the data.  
Assayed salivary cortisol values below 0.3 nmol/L and above 60 nmol/L were excluded from 
analyses.  Diurnal slope was calculated from each participant’s waking salivary cortisol value 
subtracted from their bedtime salivary cortisol value, adjusted by time between reported 
collection times for each participant, on each collection day.  Analyses with cortisol slope were 
further adjusted by reported wake time for that morning.  Both a daily value and an average 
value for each participant, calculated as the mean of their three collection day values, was 
categorized in the dataset. Two samples in each collection day were determined to be a reliable 
measure of diurnal slope, based on high correlations between diurnal slope calculated with just 
two values (waking and bedtime) and diurnal slopes calculated from four values (waking, +4 
hours, +9 hours, and bedtime) seen on multiple days in a previous sample (r=.97-.98, p<.05; 
Karissa Miller, personal communication).  Bedtime rather than a fixed point (ie, +16 hours after 
awakening) in the day was selected to maximize comparability between participants, based on 
expected inter-individual variability in typical day-length.  Based on the same sample, it was 
expected that the measurements between days would be significantly, though not highly, 
correlated (r=.39-.46, p<.05; Karissa Miller, personal communication).  Finally, one value, 
believed to estimate the overall cortisol exposure over approximately the previous 3 months 
(Stalder & Kirschbaum, 2012), was assessed for each participant from hair cortisol assays.           
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2.5 STATISTICAL ANALYSIS 
The projected recruitment goal was set at 50 participants.  Power analysis (Optimal Design 
software for nested models) suggested that n=46 at level 3 would provide 80% power with 
α=.05, moderate standardized effect size of .5, σ2=.53, 4+ observations at level 1 (number of 
within-day observations), and 7 observations at level 2 (number of days).  Standardized effect 
size was derived from moderate to large effect sizes seen in the published literature and analysis 
of SWAN FLASHES diary data when looking at the differences in negative affect, anxiety, and 
depressive symptom scores by VMS reporting, VMS frequency, and VMS bother.  The σ2 was 
derived from the level 1 variance seen in SWAN DHS, with VMS predicting next day negative 
affect. 
 Analyses were conducted with SPSS v. 20 and HLM v.7.01.  Any outliers were identified 
and addressed, the distribution of study variables was examined, and variables were categorized 
as needed. Descriptive analysis was conducted to evaluate means and frequencies of all study 
variables.  Within-day observations, with observations nested within days, and days nested 
within participants, were examined with three-level hierarchical linear models (HLM).  
Intercepts-only models were run to determine the variance in each level present for each 
outcome, and to verify that random intercepts were appropriate for these models. Associations 
between predictors and outcomes were assessed with random-coefficients models.  Covariates, 
selected based on known associations with VMS and affect, were entered into models in a 
stepwise fashion.  Base models were adjusted only by time of day of symptom reporting 
(morning, afternoon, evening), followed by demographic variables in model 2 (age, menopausal 
status, race/ethnicity, educational attainment), and finally by health-related factors (BMI or WC, 
physical activity, self-rated health, alcohol use, tobacco use) in model 3.  For all variables, 
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measures for each day of observation as well as aggregate measures across the observed period 
were calculated and retained in the dataset.  Though key variables are identified by their 
categorical terms for parsimony in the presentation of statistical analysis equations, each aspect 
of VMS, negative affect, and sleep defined below were examined in independent analyses.   
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3.0  RESULTS 
3.1 CHARACTERISTICS OF SAMPLE AT BASELINE 
A total of 53 participants completed in the study.  In order to obtain that sample, 135 women 
were screened, 62 participants were determined eligible and enrolled, 7 enrolled participants 
failed to come to their scheduled appointments and were not successfully contacted to 
reschedule, and 2 enrolled participants decided to withdraw from the study prior to their 
scheduled appointment.  Forty-four participants provided at least one day of morning and 
bedtime saliva samples that provided assays within normal limits to calculate diurnal slopes and 
daily cortisol exposure.  Thirty-seven women provided hair samples for hair cortisol sampling.  
Those who did not provide hair samples were more likely to be African American, and non-
participation in this aspect of data collection was generally due to having hair that was too short 
to provide a sufficient sample (3 centimeters required).  Participants completed 5-9 (mean, 7.77) 
days of observation, with 1-14 (mean, 5.34) diary entries entered on each day of observation.  
Forty-seven participants completed at least 4 diary entries on 6 or more days of observation. 
 Participants were generally postmenopausal and overweight.  Though not by design, the 
sample was half Caucasian and half African-American.  Participants reported relatively positive 
attitudes toward aging and menopause (mean:  2.37 out of 3, SD:  0.42), and personality measure 
scores indicating a general tendency toward agreeableness (mean:  15.77 out of 16, SD:  2.91) 
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and conscientiousness (mean:  15.68 out of 16, SD:  2.59), and lower in neuroticism (mean:  
10.67 out of 16, SD:  3.54) (table 1).   
3.2 HEALTH BEHAVIORS OF SAMPLE AT BASELINE AND DURING STUDY 
The majority of participants reported moderate levels of daily physical activity at baseline 
(69.80%).  Over the course of the observed period, most participants reported exercising 
(84.90%) and drinking caffeine (84.90%) on at least one day, while cigarette smoking was 
uncommon (20.80%).  The sample was largely split on alcohol intake (47.20% reported alcohol 
use on at least one day of the observed period) (table 2). 
3.3 VASOMOTOR SYMPTOMS 
3.3.1 Baseline 
During the telephone screen for eligibility, participants reported having typically frequent daily 
vasomotor symptoms (24.50% reporting 1-3 in a typical 24 hour period compared to 41.50% 
reporting 6 or more during that period), which they generally reported to be mild to moderate in 
severity (67.90%) and moderately or very bothersome (84.90%).  During the initial study visit, 
participants reported only moderate daily interference by their vasomotor symptoms (mean:  4.03 
out of 10, SD:  2.71) (table 3). 
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3.3.2 Daily diaries 
All participants had at least one self-reported vasomotor symptom during the observed period, 
with participants diary-reporting 7.39 (SD:  5.88) vasomotor symptoms per day on average.  
Diary reporting suggests that retrospective reporting of typical frequency may have been 
underestimated, with fewer participants reporting a mean of 3 or fewer vasomotor symptoms 
during a day of observation (18.90% in diaries vs. 24.50% in telephone screen), and more 
reporting a mean of 6 or more each day (66.00% in diaries vs. 41.50% in telephone screen).  
Participants reported a rate of fewer than one hot flash per hour awake (mean:  0.44, SD:  0.41), 
and a slightly lower rate of night sweats per hour asleep (mean:  0.34, SD: 0.28).  When broken 
down into sleep and wake vasomotor symptoms, participants reported more daily hot flashes on 
average (mean:  5.42, SD:  4.70) than night sweats (mean:  1.98, SD:  1.61).  Participants 
generally reported mild to moderate vasomotor symptom severity (mean: 1.37, SD:  0.48) and 
moderate bother (mean:  2.21, SD:  0.60) (table 3).   
3.3.3 Actigraphy 
Participants also used the event marker button on their study Actiwatches to report vasomotor 
symptoms.  The frequency reported using this method was commensurate with that of the 
diaries; 6 or more occurrences within each 24 hour period were reported by most women over 
the observed period (73.10%).  Given the similarities in this data and in order to best match 
vasomotor frequency reporting to vasomotor symptom severity and bother reporting, event 
marker data was not used in the current analyses (table 3).   
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3.4 NEGATIVE AFFECT 
3.4.1 Baseline 
Participants generally reported depressive (CESD mean: 13.53, SD: 8.68) and anxiety (ie, STAI-
trait mean:  36.45, SD:  9.34) symptom scores well below conventional cut-offs for clinical 
significance (table 4). 
3.4.2 Daily diaries 
Participants generally reported minimal levels of negative affect (PANAS-negative affect 
subscale mean:  12.10, SD:  3.71, range:  10-50; PANAS-sadness subscale mean 6.55, SD:  3.06, 
range: 5-25; Gibson scale mean 4.30, SD: 1.55, range:  3-15), and moderate levels of positive 
affect (PANAS-positive affect subscale mean:  24.70, SD: 7.18, range 10-50) (table 4).    
3.5 SLEEP ASSESSMENT 
3.5.1 Baseline 
Assessment of sleep parameters by the Pittsburgh Sleep Quality Index (PSQI) suggested largely 
problematic sleep in the sample, typical of the general population of women in this age range.  A 
majority of participants (n=38, 71.70%) had PSQI total scores over 5, indicative of poor sleep; 
the mean total score for the sample was over the clinical cut-off for poor sleep (mean:  8.06, SD: 
3.16).  Over half of the sample (n=30, 56.60%) reported typically sleeping for fewer than the 
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recommended 7 hours a night, while under half of the sample reported achieving the suggested 
sleep efficiency of 85% or more of time in bed spent actually asleep (n=23, 44.20%) (table 5). 
3.5.2 Daily diaries 
Participants generally reported that they felt moderately rested (mean: 3.93, SD: .93, range: 1-6) 
and had a moderately good night’s sleep (mean:  3.75, SD: .92, range:  1-6) the previous night 
during their morning diary entries.  However, most women (90.60%) reported that they had 
trouble sleeping the previous night during their morning diary entry on at least one day during 
the observed period (table 5).   
 Naps were also commonly reported, with an average of 2.56 (SD: 2.89) naps occurring 
over the observed period.  The majority of women (64.20%) reported taking at least one nap 
during at least one day of observation, and naps were reported on an average of 30% of days 
over the observation period.  Over 30% of women reported taking more than one nap on at least 
one day of observation (table 5). 
3.5.3 Actigraphy 
Sleep parameters measured by actigraphy generally suggested that participants overestimated 
their typical sleep duration and quality in the PSQI self-report during the baseline visit.  
Actigraphy-measured sleep duration was less than the recommended 7-8 hours/night (mean:  
5.63, SD:  0.98).  Participants exhibited over an hour of WASO on average (mean: 63.57 
minutes, SD: 36.10).  It should be noted that participants, on average, reported sleep efficiency 
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far below the optimal 85% sleep efficiency threshold (overall mean:  75.95%, SD: 11.24) (table 
5).   
3.6 CORTISOL 
3.6.1 Salivary cortisol 
Salivary cortisol values suggested that, as expected, participants had higher morning (mean 
16.82 nmol/l, SD: 7.50) than bedtime (mean 3.96 nmol/l, SD: 4.00) cortisol levels averaged 
across all three days of sampling, consistent with a negative diurnal slope.  After adjusting for 
the self-reported time between morning and bedtime collection, mean diurnal slopes of salivary 
cortisol were negative, though not particularly steep (mean slope:  -0.97, SD:  .79).  Overall 
mean cortisol exposure for each day was commensurate with morning and bedtime values (mean 
daily exposure:  10.46 nmol/l, SD:  4.46) (table 6). 
3.6.2 Hair cortisol 
Hair cortisol values fell within expected values (mean:  3.50 nmol/l, SD:  5.58).  Values were 
log-transformed for analyses due to non-normality of the distribution (table 6).   
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3.7 EXPLORATORY ANALYSES:  DIFFERENCES BY RACE/ETHNICITY 
Though not by design, the demographic make-up of the final sample allowed for direct 
comparison of primary variables by race/ethnicity.  Some significant differences between 
Caucasian and African-American participants were noted, and are detailed in the following 
paragraphs.   
 In between-women comparisons at baseline, African-American participants had greater 
BMI and waist circumference measures, while Caucasian participants reported higher levels of 
educational attainment and better self-rated health (table 1).  In contrast, no racial/ethnic 
differences were seen in the measures of personality assessed during the participants’ initial 
study visit.   
 During the initial phone screen, African-American and Caucasian participants differed 
only in their ratings of vasomotor symptom severity, with African-American women being more 
likely to rate them as typically severe (53.80%) compared to the Caucasian participants (11.10%) 
(table 3).  In daily diaries, while there were no significant racial/ethnic differences in hot flash 
frequency, severity, or bother, African-American participants were more likely to report a higher 
nightly frequency of night sweats.  
 In questionnaires, no racial/ethnic differences were seen in the measures of affect 
assessed during the participants’ initial study visit.  Diary-reported negative affect did not differ, 
but African-American women, on average, reported higher positive affect scores during their 
diary ratings (table 4). 
 Sleep issues seemed to be particularly prevalent for the African American participants in 
this sample.  On the PSQI, African-American participants were significantly less likely to report 
7 or more hours a sleep at night, less overall sleep, and higher PSQI total scores. Though sleep 
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duration did not significantly differ between the Caucasian and African-American participants, 
all other actigraphy-measured sleep parameters suggested significant race/ethnic differences.  
African-American women had more minutes of wake after sleep onset, more frequent nocturnal 
wakening, and less sleep efficiency compared to Caucasian participants (table 5).   
 Although there were no significant overall differences in mean daily average salivary 
cortisol or diurnal salivary cortisol slope by race/ethnicity, African-American participants 
exhibited significantly higher bedtime cortisol values than Caucasian participants.  
Race/ethnicity differences were also seen in hair cortisol values, with African American women 
exhibiting higher levels of cortisol concentration than their Caucasian counterparts (table 6). 
3.8 SPECIFIC AIMS 
3.8.1 Specific Aim 1:  Examine the contribution of VMS to within-day and next-day 
negative affect. 
It was hypothesized that diary-reported vasomotor symptoms would be positively associated 
with diary-reported negative affect on the same day.  This hypothesis was supported.  
Specifically, in models of observations nested within days, nested within women, daily PANAS 
negative affect as reported in daily diaries was positively associated with vasomotor symptom 
bother (B=1.46, p<0.001), and daytime hot flash bother (B=1.46, p<0.001) as reported in daily 
diaries on the same day, even after adjusting by demographic and health behavior-related 
variable.  Within days, daily PANAS sadness as reported in daily diaries was positively 
associated with vasomotor symptom bother (overall during each 24 hour period; hot flashes and 
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night sweats combined) (B=0.46, p=0.04) and daytime hot flash bother (B=0.46, p=0.04) as 
reported in daily diaries on the same day, even after adjusting by demographic and health 
behavior-related variables. Within days, daily Gibson negative affect as reported in daily diaries 
was positively associated with vasomotor symptom bother (B=0.44, p<0.01), and daytime hot 
flash bother (B=0.44, p<0.01) as reported in daily diaries on the same day, even after adjusting 
by demographic and health behavior-related variables (table 7).   
It was hypothesized that diary-reported vasomotor symptoms would be positively 
associated with diary-reported negative affect the following day.  This hypothesis was supported.  
Specifically, in models of observations nested within days, nested within women, next day 
PANAS negative affect in daily diaries was predicted by the previous day’s diary reported hot 
flash frequency rate (B=0.18, p=0.05, trend), and diary reports of the previous night’s night 
sweat severity (0.80, p=0.02) and bother (0.61, p=0.02), even after adjusting for demographic 
variables, health behaviors, the previous day’s ratings of PANAS negative affect, and ratings of 
hot flash frequency rate (for model examining previous day hot flash frequency rate), hot flash 
severity (for model examining previous night’s night sweat severity), or hot flash bother (for 
model examining previous night’s night sweat bother) on the day commensurate with affect 
ratings as outcome.   The relationship seems to specifically follow the pattern of vasomotor 
symptoms one day contributing to negative affect the following day; when next day hot flash 
frequency rate is entered as the outcome in an otherwise equivalent model, no relationship is 
seen between previous day negative affect and next day hot flash frequency rate (B=0.01, 
p=0.33).  Next day Gibson negative affect in daily diaries was also associated with the previous 
night’s night sweat severity (0.62, p<0.01) and bother (0.35, p=0.03), even after adjusting for 
demographic variables, health behaviors, the previous day’s ratings of Gibson negative affect, 
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and ratings of hot flash severity (for model examining previous night’s night sweat severity), or 
hot flash bother (for model examining previous night’s night sweat bother) on the day 
commensurate with affect ratings as outcome (table 8). 
3.8.2 Specific Aim 2:  Examine sleep as a mediator of the association between VMS and 
next-day negative affect. 
It was hypothesized that sleep disruption, as measured by actigraphy, would partially explain the 
relationship between vasomotor symptoms and following day negative affect, as measured by 
diary reporting.  In models of observations nested within days, nested within women, the role of 
sleep as a mediator of the association between vasomotor symptom experience and next-day 
negative affect was not supported in this sample.  The frequency rate of night sweats reported 
was not associated with next day negative affect, and therefore not further assessed.  Night sweat 
bother as reported the morning after actigraphy was associated with next day Gibson negative 
affect (B=0.29, p=.02), but equivalent with the introduction of sleep duration or sleep efficiency 
in the model.  There was a slight increase in this coefficient with the introduction of WASO into 
the model (B=0.32, p=02).  Similar results were seen in the relationship between night sweat 
severity and next day negative affect.  Night sweat severity as reported the morning after 
actigraphy was associated with next day PANAS negative affect (B=0.78, p=0.01) and next day 
Gibson negative affect (B=.48, p<.01).  These coefficients increased slightly with the addition of 
sleep duration (PANAS, B=.86, p=0.01; Gibson, B=.51, p<.01), sleep efficiency (PANAS, 
B=.86, p=0.01), and WASO (PANAS, B=.85, p=0.01; Gibson, B=.53, p<.01), suggesting that the 
relationship between night sweat severity and negative affect is independent of sleep parameters, 
and even strengthened when sleep parameters are held constant (Table 9).   
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3.8.3 Specific Aim 3a:  Examine diurnal cortisol slope and hair cortisol as physiologic 
measures associated with negative affect, vasomotor symptoms, and sleep parameters. 
It was hypothesized that diurnal cortisol slope would be positively associated with negative 
affect.  This hypothesis was supported.  As expected, in models of daily observations nested 
within women, diurnal cortisol slope was significantly and positively associated with measures 
of negative affect (PANAS NA B=0.68, p=.01; PANAS Sadness B=0.43, p<.001), such that a 
flatter diurnal cortisol slope was related to higher negative affect scores.  Mean daily cortisol 
exposure also showed a significant association with PANAS sadness (B=0.07, p=0.03).  These 
relationships held in fully adjusted models, including demographic variables and assessment of 
daily diary-reported health behaviors (table 10).  In models of hair cortisol values and overall 
mean negative affect values for each woman, no significant relationships with transformed or 
non-transformed hair cortisol and negative affect variables were exhibited in unadjusted or fully 
adjusted models (data not shown).      
It was hypothesized that diurnal cortisol slope would be positively associated with 
vasomotor symptoms.  This hypothesis was supported.  In models of daily observations nested 
within women, diurnal cortisol slope was significantly and positively associated with some 
measures of vasomotor experience, such that a flatter slope was related to higher vasomotor 
symptom ratings.  Specifically, a flatter diurnal cortisol slope was related to increased reports of 
vasomotor symptom severity (B=0.06, p=0.02), hot flash severity (B=0.09, p=0.03), and hot 
flash bother (0.10, p<0.01).  These relationships held in fully adjusted models, including 
demographic variables and assessment of daily diary-reported health behaviors (table 11). In 
models of hair cortisol values and overall mean vasomotor symptom values for each woman, 
higher hair cortisol values were associated with overall increased daily hot flash frequency rate 
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(B=0.05, p=0.01), even after adjusting for demographic and health behavior-related variables 
(table 11).     
It was hypothesized that diurnal cortisol slope would be associated with sleep parameters, 
such that a flatter slope would be related to measures of poor sleep.  This hypothesis was 
partially supported.  Specifically, in models of mean daily observations nested within women, 
shorter sleep duration (B=-0.38, p<0.01) but less time awake after sleep onset (B=-7.62, p=0.02) 
was seen the night prior to a flatter diurnal cortisol slope. Longer sleep duration (B=.40, p=.04) 
was observed the night following a flatter diurnal cortisol slope.  This relationship held in fully 
adjusted models, including demographic variables and assessment of daily diary-reported health 
behaviors.  Higher mean cortisol exposure over the observed period was associated with more 
time awake after sleep onset (B=2.68, p=0.02) and reduced sleep efficiency (B for log-
transformed variable=-.004, p=0.03).  These relationships held in fully adjusted models, 
including demographic variables and assessment of daily diary-reported health behaviors (table 
12).  In models of hair cortisol values and overall mean actigraphy-measured sleep values for 
each woman, no significant relationships were seen in unadjusted or fully adjusted models (data 
not shown). 
3.8.4 Specific Aim 3b:  Examine cortisol as a mediator linking vasomotor symptoms with 
negative affect. 
It was hypothesized that a flatter diurnal cortisol slope would partially explain the relationship 
between vasomotor symptoms and same day negative affect.  This hypothesis was supported.  
Mediation was then tested with two-level hierarchical models using the Krull-MacKinnon 
method (Krull & MacKinnon, 1999).  In the first step (1), negative affect was predicted from 
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same day VMS with two-level hierarchical linear regression.  In the second step (2), cortisol 
slope was included in the regression model in order to estimate negative affect from both VMS 
and cortisol (A).  The difference between the estimates of the VMS variable in the first and 
second equation estimated the extent to which cortisol accounts for the relationship between 
VMS and same day negative affect.  Specifically, in models of mean daily observations nested 
within women, the significant association between hot flash frequency rate and measures of 
negative affect was not affected by the inclusion of diurnal cortisol slope in the model (Gibson 
NA: -.31, p=0.04).  However, hot flash severity and measures of negative affect remained 
significant but were reduced when diurnal cortisol slope was introduced into otherwise 
equivalent, fully adjusted models (PANAS NA:  HF severity B=2.28, p<0.01, with diurnal slope, 
B=2.16, p<0.01; Gibson NA:  HF severity B=0.83, p<.001, with diurnal slope, B=0.61, p=.048).  
When examining diurnal cortisol slope as a mediator linking hot flash bother and measures of 
negative affect, there was no significant change in the coefficients for PANAS NA (B=1.73, 
p<.01), but a relatively large change in another measure, with hot flash bother no longer 
significantly associated with negative affect after including diurnal cortisol slope in the model 
(Gibson NA:  B=0.49, p=0.04, with diurnal slope, B=0.28, p=0.17) (table 13).   
Mediation was also tested with aggregate variables in linear regression using the Sobel method 
((Sobel, 1982).  No significant results were found using this model, with cortisol and negative 
affect compared between women (data not shown).  As hair cortisol was not associated with 
negative affect or vasomotor symptom experience in independent models, further mediational 
analyses were not conducted using these parameters.   
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3.9 EXPLORATORY ANALYSES:  DIFFERENCES BY RACE/ETHNICITY 
The ability to fully explore moderation by race/ethnicity in the specific aims presented above 
was limited by the relatively small sample and large number of relevant covariates.  However, 
exploratory analyses suggested some differences in the pattern of results by race/ethnicity that 
merit additional study.   
 The relationship between vasomotor symptom experience and same day negative affect 
(specific aim 1a) may be strongest among African American participants.  Specifically, effect 
modification was seen in the relationship between vasomotor symptom bother and PANAS 
negative affect by race (interaction term p<.01), and for hot flash bother and Gibson negative 
affect by race (interaction term p=0.04).  This relationship was also seen in the relationship 
between vasomotor symptoms and next day negative affect (specific aim 1b), such that hot flash 
bother more strongly predicted next day Gibson negative affect among African American 
participants than Caucasian participants (interaction term p=0.04).  Exploratory moderation 
analyses by race/ethnicity suggest that the relationship between a flatter cortisol slope and 
daytime hot flash severity (Specific Aim 3a) is stronger among the African American 
participants (interaction term p=.04).  No other differences in relationships by race/ethnicity were 
seen with other vasomotor symptom-related outcomes. 
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4.0  DISCUSSION 
This study aimed to examine the within day and day-to-day relationships between vasomotor 
symptoms and negative affect, and the potential role of sleep disturbance and cortisol 
dysregulation in these relationships, using ambulatory and physiological data among a sample of 
relatively healthy women in midlife.  After accounting for a number of health and demographic 
variables, it was found that women reported more negative affect on both the same day and the 
day following a more negative experience of vasomotor symptoms.  A flatter diurnal cortisol 
slope partially explained the same day relationship between vasomotor symptoms and negative 
affect, while sleep disturbance did not appear to play a role in linking previous day hot flashes or 
night sweats to next day negative affect.   
Participants reported more negative affect on the days that they also reported more 
bothersome vasomotor symptoms.  While an association between vasomotor symptoms and 
negative affect has been commonly found in a growing literature (Blümel et al., 2004;  
Bromberger et al., 2003, p. 20; Bromberger & Kravitz, 2011;Bromberger et al., 2001, p. 200; 
Burleson et al., 2010; Collins & Landgren, 1994; Freeman et al., 2005; Gibson et al., 2011; Gold 
et al., 2006; Hunter, Gupta, Papitsch-Clark, & Sturdee, 2009; Ishizuka et al., 2008; Joffe et al., 
2002; Li, Yu, Ma, Sun, & Yang, 2008; Thurston et al., 2008, 2005), most studies have examined 
only vasomotor symptom occurrence, with both vasomotor symptom and mood reporting limited 
by retrospective recall.  The findings of the current study extends the prior literature by utilizing 
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multiple aspects of vasomotor symptom experience and negative affect, and measuring each with 
ambulatory data to capture self-reported experiences shortly after they occur throughout the daily 
lives of midlife participants.  Given the common prevalence of vasomotor symptoms among 
women in midlife, understanding the aspects of vasomotor symptom experience that may 
contribute to mood disturbance among symptomatic women is essential for informing 
intervention and research efforts.  Further, understanding the mechanisms underlying the 
association between negative affect and vasomotor symptom experience in the daily lives of 
women in midlife may help to inform intervention efforts to improve quality of life and health 
among symptomatic women throughout the menopausal transition.   
  In a novel finding, this study suggests that cortisol dysregulation is related to vasomotor 
symptoms, and may play a role in the daily relationship between vasomotor symptom experience 
and negative affect.  Specifically, vasomotor symptom severity and bother, though not 
frequency, were associated with flatter diurnal cortisol slopes in the current study.  This finding 
contributes to the previously sparse empirical evidence linking vasomotor symptom severity 
(Cagnacci et al., 2011; Woods et al., 2006) and occurrence (Cignarelli et al., 1989; Genazzani et 
al., 1984; Meldrum et al., 1984) with cortisol dysregulation, and improves upon past 
methodological limitations including use of urinary cortisol (Cagnacci et al., 2011; Woods et al., 
2006), a single day of salivary cortisol measurement (Sievert, 2012), and very small sample sizes 
(Cignarelli et al., 1989; Genazzani et al., 1984; Meldrum et al., 1984).  Consistent with past 
studies (Heaney et al., 2010; Knight, Avery, Janssen, & Powell, 2010), diurnal cortisol slope in 
this sample was also flatter on average among women who reported more negative affect.  The 
interrelationships between these factors were further investigated, and it was found that a flatter 
diurnal cortisol slope appears to explain some of the variance in the relationship between self-
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reported vasomotor symptom severity, bother, and negative affect in the daily life of 
symptomatic women. 
These findings may lend support to the hypothesis that as an unpredictable stressor often 
occurring in social contexts, and anecdotally reported as embarrassing and highly noticeable 
(Smith et al., 2011), vasomotor symptoms may trigger stress-related cortisol release and higher 
overall cortisol exposure across the day (Meldrum et al., 1984).  Specifically, vasomotor 
symptoms that are perceived as severe or bothersome are more likely to be processed as a socio-
evaluative threat, the type of stressor known to most strongly elicit cortisol reactivity (Dickerson 
et al., 2008).  High levels of cortisol reactivity and consequent high levels of cortisol exposure 
are thought to result in the dysregulation of diurnal cortisol rhythms (Woods et al., 2006) linked 
to negative affect (Knight et al., 2010).  Vasomotor symptoms that are perceived as bothersome 
may therefore elicit stress-related cortisol release, contributing to negative affect and cortisol 
dysregulation over time.     
Though these findings contribute support to a theoretical model of negative perception of 
vasomotor symptom experience contributing to cortisol reactivity, many assumptions remain.  In 
the current study, reactivity was not studied, and can only be assumed to play a role in the 
proposed fashion.  As analysis was limited to the nested and aggregate mean of cortisol slope 
and negative affect on the days of salivary sample collection, the direction of effect cannot be 
determined.  Further, investigation of overall cortisol exposure as measured by mean daily 
salivary cortisol exposure and hair cortisol, presumed to be an important factor in cortisol 
dysregulation, did not show the same patterns of associations with vasomotor symptoms or 
negative affect as diurnal slope.  The theoretical pathway linking daily cortisol dysregulation to 
daily negative affect is tenuous at best, and remains to be clarified.  Alternative pathways, such 
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as circadian dysregulation underlying cortisol dysregulation as well as vasomotor symptoms and 
negative affectivity, may also be considered.  The findings of the current study therefore provide 
a novel contribution to our knowledge of the relationship between cortisol and vasomotor 
symptoms, and are promising for further understanding the complex relationship between 
vasomotor symptom experience and negative affect in daily life, while also raising a number of 
questions to be pursued in future research.       
  In addition to co-occurring on the same day, vasomotor symptom experience was 
associated with increased next day negative affect.  Specifically, women reported more negative 
affect the day after reporting more frequent hot flashes, and after reporting more bothersome or 
severe night sweats the previous night.  These relationships were seen even after adjusting for 
previous day negative affect and same day vasomotor symptoms, in addition to demographic and 
health behavior-related variables.  Temporal relationships between vasomotor symptoms and 
mood, particularly on a daily basis, have rarely been investigated.  These findings contribute to 
this limited literature by replicating and extending those of Burleson et al. (Burleson et al., 2010) 
and Gibson et al. (Gibson et al., 2011), which found that the occurrence of any vasomotor 
symptoms was associated with next day negative affect, independent of negative affect the 
previous day and vasomotor symptom reporting the same day.  While the previous studies had 
limited measures of both affect and the presence or absence of undifferentiated hot flashes or 
night sweats in the previous 24 hours, these findings allow for investigation of the role of hot 
flashes compared to night sweats, as well as different aspects of vasomotor symptom experience, 
in relationship to commonly used measures of negative affect.   
It had been hypothesized that the relationship between vasomotor symptoms and next day 
negative affect was driven by the experience of night sweats during the intervening night, a 
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model known as the domino hypothesis (Joffe et al., 2009).  The contribution of self-reported 
vasomotor symptoms to perceived sleep disturbance among women in midlife has been 
supported in a number of cross-sectional studies, and disturbed sleep is known to impact 
psychological functioning and next-day mood.  However, an association between self-reported or 
physiologically measured night sweats and objective measures of sleep, essential to this 
hypothesis, has not been well-supported by empirical evidence.  Similarly, the frequency of self-
reported night sweats was not related to actigraphy-measured sleep parameters in the current 
study, as would be expected if the occurrence of night sweats was disruptive to sleep.  It 
therefore does not appear that the night sweats themselves contributed to sleep disturbance in this 
sample.  In contrast to reported night sweat frequency, subjective ratings of night sweat severity 
and bother, as reported the following morning, were related to actigraphy measures of sleep 
duration and sleep efficiency.  These sleep parameters were also associated with next day 
negative affect; mediational analyses suggest that they do not explain the relationship between 
night sweat bother or severity and next day negative affect.   
A number of factors may explain this pattern of findings.  Foremost, information on night 
sweats derived from self-report may not be highly representative of women’s experience of these 
symptoms.  As reporting occurs in the morning following awakening, self-report necessitates a 
longer period of retrospective recall than the frequent within-day reporting schedule.  
Additionally, accuracy of self-report is coupled with the complication of potential sleepiness at 
the time of reporting, as well as at the time of symptom occurrence, which may affect recall.  
Women may not have been aware of or remember events with onset during sleep, with the 
exception of those events that were particularly disruptive (commensurate with higher severity 
rating as defined) or bothersome (assuming that bother is related to wakefulness).  Alternatively, 
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over-reporting or more negatively biased reporting of the subjective experience of night sweats 
during the previous night may result from having had a poor night’s sleep.  Regardless of 
occurrence, women may report a more negative experience of overnight vasomotor symptoms as 
attribution to their wakefulness the previous night, current lack of feeling rested, and impaired 
psychological functioning.   
Actigraphy-measured sleep parameters were also related to cortisol slope, both the night 
prior to and the night following measurement.  Specifically, a flatter diurnal cortisol slope was 
related to shorter sleep duration, though less time awake after sleep onset, the night prior to 
cortisol sampling.  That is, after a night of less sleep, women exhibited flatter diurnal cortisol 
slopes.  This is consistent with past studies, in which a flatter diurnal slope is related to self-
reported shorter sleep as well as greater sleep disruption in a sample of midlife men and women 
(Kumari et al., 2009), and may be related to findings that sleep deprivation contributes to 
elevated resting cortisol levels and exaggerated cortisol response to a laboratory-based socio-
evaluative stress task (Minkel et al., 2014).  It is possible that shorter sleep as measured by 
actigraphy may set the stage for both cortisol dysregulation and negative affect, exacerbating the 
role of vasomotor symptom bother and severity in contributing to both during the day.  However, 
after a day in which women exhibited flatter diurnal cortisol slopes, they had longer sleep.  
Overall cortisol exposure was associated with less efficient sleep and more time awake after 
sleep onset.  The complex and likely bidirectional relationships between these behavioral and 
physiological factors in midlife remain unclear, and warrant future investigation.   
The experience of vasomotor symptoms and negative affect, and the factors that link 
them, may differ among women from different racial/ethnic backgrounds.  The study sample was 
fairly equally split between African American and Caucasian women, allowing for the 
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opportunity to conduct exploratory analyses on race/ethnic differences on the significant findings 
within each specific aim.  Most importantly, stronger relationships between vasomotor symptom 
bother and both same day and next day negative affect reporting were seen in African American 
participants compared to their Caucasian peers.  Though past studies have suggested that African 
American women report vasomotor symptoms as more bothersome (Thurston et al., 2008), this is 
the first known study to demonstrate moderation by race/ethnicity of the relationship between 
daily measurements of negative affect and vasomotor symptom experience.  These relationships 
were not seen to vary by race/ethnicity in Gibson et al. (Gibson et al., 2011), perhaps because 
only the presence/absence of vasomotor symptoms, and not the subjective experience of 
vasomotor symptom bother, were measured in that study.    
Additionally, a novel finding concerns the association found between diurnal cortisol and 
vasomotor symptoms.  As mentioned previously, there is very little empirical evidence 
surrounding the proposed relationship between cortisol and vasomotor symptoms, and the few 
studies that have investigated this relationship did not examine, or have sufficient sample 
composition to examine, moderation by race/ethnicity.  However, findings from the current study 
suggest that the relationship between hot flash severity and a flatter diurnal cortisol slope may be 
stronger among African American than Caucasian participants.  The relationship between hot 
flash severity and cortisol seen in the sample may be due to the patterns of severity reporting in 
these two groups, which has a more restricted range and overall more likely to be reported as 
mild among the Caucasian women compared to the African American women in this sample.  It 
may also reflect a mechanism by which African American women in the menopausal transition 
have an increased risk of the cardiovascular risk factors thought to be related to cortisol 
dysregulation and hypercortisolemia; that is, African American women are more likely to report 
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more severe hot flashes, which among that group are more likely to contribute to unhealthy 
cortisol patterning.  There is a limited ability to determine temporality in this data; it is also 
possible that the flatter cortisol slopes seen among the African American women in this sample 
may play a role in increasing hot flash severity due to underlying effects on the hypothalamic-
pituitary-ovarian axis (Woods et al., 2006).  These findings should be interpreted with an 
abundance of caution given concerns about sample size and power to determine interactions by 
race/ethnicity, but as much remains unknown about race/ethnic differences between risk factors 
and health outcomes as pertains to the menopausal transition, they yield interesting hypotheses to 
be pursued in future research.   
A number of other findings are worth mentioning relating to risk for negative affect, 
vasomotor symptoms, cortisol dysregulation, and poor sleep in this sample.  In the overall 
sample, women with higher levels of educational attainment were less likely to report negative 
affect the same and following day, while cigarette smoking during the observed period was 
related to increased negative affect reporting in some models.  Cigarette smoking had an even 
stronger impact on next day negative affect reporting.  Self-rated health was also protective 
against some measures of same day and next day negative affect reporting in some models.  
Surprisingly, self-reported exercise during the observation contributed to next day negative 
affect.  Sleep duration was reduced among with higher levels of education and among 
postmenopausal women compared to perimenopausal women; postmenopausal women spent less 
time awake after sleep onset.  Women who reported less than excellent health slept longer than 
those in excellent health, though exhibited more fragmented sleep and more time spent awake 
after sleep onset.  Both sleep duration and WASO were measured as reduced on nights following 
reported alcohol use, limited to only a yes/no response; after drinking, women slept less, but also 
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spent less time awake after they fell asleep.  Though the majority of these demographic and 
health behaviors exhibited expected relationships with vasomotor symptoms, negative affect, and 
sleep parameters, the replication of these associations with ambulatory data collection provides 
useful information about the role of these factors in the daily life of women in midlife.      
This study had some limitations that warrant mention.  Eligibility criteria mandated that women 
have daily vasomotor symptoms, and not currently be taking any psychotropic medications, 
cortisol supplements or medications, or hormone therapy.  Additionally, participants who 
completed the study had to be both willing and able to come to the study site and be compliant 
with frequent entries in an electronic daily diary over the course of a week, as well as wear an 
Actiwatch and collect saliva samples on a time-dependent schedule.  Participation therefore 
required that women be relatively healthy and possess a high level of motivation and 
compliance, which may not be representative of all women in midlife.  It should also be noted 
that this sample was unique; participants reported poor sleep and frequent naps, perhaps 
reflective of the high level of unemployment and inconsistent daily schedules indicated by many 
in the sample.  Commensurate with the demands on participant’s time for the week of the study 
that participation involved, issues related to missing data were a concern.  Missing data was 
primarily problematic with saliva and hair cortisol samples, due to equipment failure, user error 
or ineligibility, and participant forgetfulness.  This was particularly true of hair cortisol, which 
was collected from only a subset of participants who were both willing and had hair long enough 
to sufficiently participate in this optional aspect of the protocol.  Therefore, the full scope of 
experience may not have been adequately captured in this study design, and data may be biased 
toward days in which participants had fewer stressors and negative events interfering with their 
compliance.  The overall model, specified a priori, includes assumptions about the temporality of 
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relationships between vasomotor symptom experience, cortisol, and negative affect, which may 
not be an accurate reflection of the relationship between these factors.  Additionally, unmeasured 
variables (ie, employment status/history, social support, marital status) may play important roles 
that cannot be determined in the absence of their inclusion.  Finally, the sample size of the study, 
while powered to capture any primary associations between diary-reported vasomotor symptoms 
and negative affect if they occurred, may limit the ability to fully interpret all aims.  This is 
particularly true of exploratory analyses by race/ethnicity, and analysis on limited samples such 
as those with complete salivary and/or hair cortisol data available.   
Despite these limitations, this study also had considerable strengths.  Foremost among 
these is the use of electronic daily diaries for ambulatory assessment of vasomotor symptoms and 
negative affect.  Though the technical competence and compliance required of these measures 
may limit generalizability, utilization of these technologies presents a major advancement from 
the typical retrospective recall, likely colored by mood in the moment and subject to failures of 
memory, of most studies assessing vasomotor symptoms.  Further, this allowed for nuanced 
collection of multiple aspects of symptom and mood experience, including temporal variation, to 
be explored in future study, aspects of vasomotor symptom experience including severity and 
bother in addition to frequency, and the ability to separate night sweats from daytime hot flashes.  
A wide array of mood items, asked on a Likert scale, allowed for the construction of multiple 
mood measures and was designed to reduce response bias.  Similarly, the use of actigraphy in 
addition to self-reported sleep evaluation allowed for a more objective measure of a variety of 
sleep parameters.  The length of the study, 7 days of observation, was designed around the 
greatest validity for these actigraphy-based sleep measures.   
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An additional strength of this study was the use of three days of cortisol sampling to 
determine a mean diurnal slope and mean affective measures for each participant across several 
days, given the known day-to-day variability in these measures (Segerstrom, Boggero, Smith, & 
Sephton, 2014; Whitehead & Bergeman, 2014).  The utilization of novel hair cortisol assaying 
techniques further adds to our knowledge of the relationship between cortisol and a number of 
factors, and may better get at chronic cortisol exposure rather than salivary or urinary cortisol’s 
short-term snapshot.  Further, hair collection avoids the possibility of participant forgetfulness 
and error inherent in time-dependent saliva sample collection.  Finally, although the sample size 
was too small too thoroughly and confidently assess interactions by race/ethnicity, the racial 
composition of the sample allowed for some investigation of the differing relationships by race 
between these common aspects of the menopausal experience, further informing our knowledge 
in this important area.   
The current study contributes to our understanding of some aspects of the relationship 
between mood and menopausal symptoms, while raising additional questions for future study.  A 
number of additional avenues remain to be addressed using the data collected for this study, and 
not included in analyses of these primary aims.  Foremost among these are an investigation of 
the roles of various individual differences, including personality factors; the role of both self-
reported typical health behaviors in conjunction with actigraphy and diary reporting; 
questionnaire-based assessments of typical negative affect in conjunction with diary reporting of 
daily negative affect; and reported duration of vasomotor symptoms; in the relationships seen 
between vasomotor symptoms and negative affect.  Additional factors that were assessed and 
remain to be explored include the role of napping, measures of positive affect, and attitudes 
toward aging and menopause.  The hypothesis that vasomotor symptoms are processed as 
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socioevaluative threat, contributing to cortisol response, can be further investigated with 
examination of questionnaires assessing the perceived impact of vasomotor symptoms on daily 
life, as well as diary data about social interactions and patterns throughout the day.  Alternately, 
the role of underlying circadian rhythm dysregulation as a contributor to both cortisol 
dysregulation and VMS may be explored in part with the data collected in this study.  Uniquely, 
the ambulatory data collected can allow for additional examination of the patterns of temporal 
variation in vasomotor symptoms, mood, and the relationships between them, with an eye to 
investigating the circadian patterns of these factors and how they relate to other circadian 
rhythms, such as sleep and social rhythms as reported in the diaries.  A number of relevant 
factors collected in the current dataset remain to be explored in a continuing effort to better 
understand the relationships between vasomotor symptom experience, negative affect, and health 
among women in midlife.       
The findings of this study suggest that vasomotor symptom bother is the key factor 
related to various aspects of affect and health.  Clinical research is needed to determine whether 
interventions can shift women’s subjective perceptions of their vasomotor symptom experience, 
and if reductions in perceptions of bother rather than frequency in turn improve the affective and 
physiological stress response to their occurrence.  Given the importance of these factors for 
quality of life as well as in the development of cardiovascular risk factors, intervention efforts 
should focus not on reducing symptom frequency, but on reframing women’s attitudes towards 
symptoms themselves.   
Such intervention studies may also include psychoeducation around sleep to improve 
sleep hygiene and patterns for affected women, reframing previously held beliefs that night 
sweats cause poor sleep which may get in the way of women taking ownership over their 
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problematic sleep patterns and how to address them.  Offering psychoeducation on a more 
nuanced view of the relationship between mood and menopausal symptoms and women’s 
perceptions of sleep quality may offer an opportunity to improve all.  Additionally, advances in 
mobile technology provide improved ability to assess or possibly influence women’s perception 
of hot flashes/night sweats as they occur, and examine concomitant changes in mood and stress 
response, in order to improve both data collection and intervention dissemination.  Further, the 
use of mobile technology may provide a venue to help women empower themselves to take 
control of the impact that these common symptoms have on their lives and their health, while 
also providing the opportunity to advance research on the role of health behaviors and lifestyle 
modification on symptom reduction.   
In summary, using ambulatory methods to fully characterize and relate daily vasomotor 
symptom and affective experiences of women across a typical week, actigraphy to assess sleep 
parameters independent of reporting bias, and both hair collection and three days of saliva 
sampling to examine cortisol dysregulation and exposure, this study aimed to improve our 
understanding of the temporal relationships between these factors and the role of health 
behaviors and biological mechanisms that may link them.  In the current study, women reported 
more negative affect on the same day that they also reported more frequent or bothersome 
vasomotor symptoms, and on the day following a night in which they experience severe and/or 
bothersome night sweats.  The relationship between same day vasomotor symptom experience 
and negative affect may be partially explained by cortisol dysregulation, with cortisol stress 
response possibly triggered by the subjective experience of vasomotor symptoms perceived to be 
bothersome.  The relationship between vasomotor symptoms, and specifically night sweats, and 
next day negative affect remains to be clarified.  Sleep disturbance is independently related to 
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bothersome or severe night sweats and next day negative affect, but does not explain the 
relationship between night sweats and next day negative affect.  The interrelationship of these 
factors may rest on subjective sleep quality, colored not by the disruptive occurrence of night 
sweats, but by the negative attributions of the experience of those symptoms experienced by 
many women.  These findings may have implications for both research and clinical applications, 
with an emphasis on shifting attention away from concern about vasomotor symptom occurrence 
and frequency, and toward understanding and reducing symptom bother among women in 
midlife to improve quality of life and potential downstream effects on mood, health, and 
physiologic function.   
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Figure 1. A priori model with disturbed sleep and cortisol dysregulation linking VMS and negative affect. 
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Figure 2.  Aim 1:  VMS predicting same-day and next-day negative affect 
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Figure 3.  Aim 2:  Role of sleep disturbance in relationship between VMS and next-day negative affect. 
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Figure 4.  Aim 3a:  Diurnal cortisol as a correlate of VMS, negative affect, and sleep parameters. 
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Figure 5.  Aim 3b:  Role of cortisol in relationship between VMS and negative affect. 
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Table 1. Characteristics of sample at baseline (n=53) 
     
  
Caucasian African American Total 
(n=27, 50.98%) (n=26, 49.02%) (n=53) 
  Mean (SD) Mean (SD) Mean (SD) 
Age 53.44 (5.20) 53.15 (3.84) 53.31 (4.54) 
Duration of vasomotor symptoms 
(years) 4.25 (4.40) 6.31 (6.80) 5.26 (5.74) 
Body mass index (m/kg
2
)* 27.36 (5.09) 31.78 (7.50) 29.53 (6.70) 
Waist circumference (cm)* 89.63 (12.59) 102.96 (14.17) 96.03 (14.84) 
Attitude Toward Aging and 
Menopause (Scale 1-3)± 
2.46 (.38) 2.27(.45) 2.37 (.42) 
Mini-IPIP (Scale 4-16) 
   
Extraversion 13.22 (3.36) 12.85 (3.65) 13.04 (3.47) 
Agreeableness 15.96 (3.08) 15.56 (2.76) 15.77 (2.91) 
Conscientiousness 16.00 (2.58) 15.36 (2.61) 15.68 (2.59) 
Neuroticism 9.88 (3.41) 11.48 (3.55) 10.67 (3.54) 
Intellect/Imagination 13.79 (3.32) 14.27 (2.92) 14.04 (3.10) 
  n (%) n (%) n (%) 
Menopausal status 
  
  
  
  
  
  
Perimenopausal 6 (22.20) 7 (26.90) 13 (24.50) 
Postmenopausal 21 (77.80) 19 (73.10) 40 (75.50) 
Education* 
   High school degree or less 5 (18.50) 19 (73.10) 24 (45.30) 
Some college 10 (37.00) 4 (15.40) 14 (26.40) 
College degree or beyond 12 (44.40) 3 (11.50) 15 (28.30) 
Self-Rated Health*     
Excellent/very good 19 (70.40) 10 (38.50) 29 (54.70) 
Good/fair/poor 8 (29.60) 16 (61.50) 24 (45.30) 
Body mass index (categorical)    
Normal weight (18.5-24.5) 9 (33.30) 4 (15.40) 13 (24.50) 
Overweight (25-29.9) 12 (44.40) 10 (38.50) 22 (41.50) 
Obese (>30)** 6 (22.20) 12 (46.20) 18 (34.00) 
Mean comparisons by ANOVA, categorical by chi-square    
*p<.05 
**p<.09 
± Higher scores are considered positive 
Mini-IPIP:  Mini-International Personality Item Pool 
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Table 2. Health behaviors of participants at baseline and during observation 
  
Caucasian 
(n=27, 49.02%) 
African 
American 
(n=26, 50.98%) 
Total 
(n=53) 
n (%) n (%) n (%) 
Baseline visit questionnaires    
Habitual physical activity (IPAQ-SF)    
Low Physical Activity 9 (33.30) 7 (26.90) 16 (30.20) 
Moderate Physical Activity¥ 18 (66.70) 19 (73.10) 37 (69.80) 
Electronic diaries    
Report alcohol intake on at least one day of 
observation 
   
Yes 12 (44.40) 13 (50.00) 25 (47.20) 
No 15 (55.60) 13 (50.00) 28 (52.80) 
Report caffeine intake on at least one day of 
observation 
   
Yes 22 (81.50%) 23 (88.50) 45 (84.90) 
No 5 (18.50) 3 (11.50) 8 (15.10) 
Report cigarette use on at least one day of 
observation** 
   
Yes 3 (11.10) 8 (30.80) 11 (20.80) 
No 24 (88.90) 18 (69.20) 42 (79.20) 
Report exercise on at least one day of 
observation 
   
Yes 24 (88.90) 21 (80.80) 45 (84.90) 
No 3 (11.10) 5 (19.20) 8 (15.10) 
Mean comparisons by ANOVA, categorical by chi-square    
*p<.05 
**p<.09 
¥ IPAQ-SF:  International Physical Activity Questionnaire, Short Form, completed at initial visit.  
Moderate physical activity defined as “a level of activity equivalent to half an hour of at least moderate-
intensity physical activity on most days” 
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 Table 3. Vasomotor symptoms at baseline and during observation 
 
Caucasian 
(n=27, 50.98%) 
African American 
(n=26, 49.02%) 
Total 
(n=53) 
n (%) n (%) n (%) 
Telephone screen 
   
Number of vasomotor symptoms  
per 24 hours 
   1-3 7 (25.90) 6 (23.10) 13 (24.50) 
4-5 8 (29.60) 10 (38.50) 18 (34.00) 
6+ 12 (44.40) 10 (38.50) 22 (41.50) 
Vasomotor symptom severity* 
   
Mild/moderate 24 (88.90) 12 (46.20) 36 (67.90) 
Severe 3 (11.10) 14 (53.80) 17 (32.10) 
Vasomotor symptom bother 
   Not at all/very little 5 (18.50) 3 (11.50) 8 (15.10) 
Moderately/a lot 22 (81.50) 23 (88.50) 45 (84.90) 
Baseline questionnaires mean (SD) mean (SD) mean (SD) 
Hot Flash Daily Interference Score 
Mean (Scale 0-10) 3.42 (2.33) 4.67 (2.97) 4.03 (2.71) 
Electronic diaries n (%) n (%) n (%) 
Number of vasomotor symptoms 
per 24 hours 
   <1-3 6 (22.30) 4 (15.40) 10 (18.90) 
4-5 3 (11.10) 5 (19.20) 8 (15.10) 
6+ 18 (66.70) 17 (65.40) 35 (66.00) 
Vasomotor symptom severity  
   Mild/moderate 26 (96.30) 25 (96.20) 51 (96.20) 
Severe 1 (3.70) 1 (3.80) 2 (3.80) 
Vasomotor symptom bother  
   Not at all/very little 12 (44.40) 10 (38.50) 22 (41.50) 
Moderately/a lot  15 (55.60) 16 (61.50) 31 (58.50) 
Number of daytime hot flashes  
   <1-3 2 (7.40) 9 (34.60) 11 (20.80) 
4-5 7 (25.90) 3 (11.50) 10 (18.90) 
6+ 18 (66.70) 14 (53.80) 32 (60.40) 
Hot flash rate (number per hour 
awake) .34 (.29) .53 (.48) .44 (.41) 
Hot flash severity  
   Mild/moderate 26 (96.30) 25 (96.20) 51 (96.20) 
Severe 1 (3.70) 1 (3.80) 2 (3.80) 
Hot flash bother  
   Not at all/very little 11 (40.70) 8 (30.80) 19 (35.80) 
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Moderately/a lot  16 (59.30) 18 (69.20) 34 (64.20) 
Number of night sweats per night 
   <1-3 8 (29.60) 9 (34.60) 17 (32.10) 
4-5 1 (3.70) 5 (19.20) 6 (11.30) 
6+ 18 (66.70) 12 (46.20) 30 (56.60) 
Night sweat rate (number per hour 
asleep)* .24 (.19) .44 (.32) .34 (.28) 
Night sweats severity    
Mild/moderate 26 (96.30) 23 (88.50) 49 (92.50) 
Severe 1 (3.70) 3 (11.50) 4 (7.50) 
Night sweats bother  
   Not at all/very little 12 (44.40) 14 (53.80) 26 (49.10) 
Moderately/a lot  15 (55.60) 12 (46.20) 27 (50.90) 
Actigraphy event marker press n (%) n (%) n (%) 
Number of vasomotor symptoms  
per 24 hrs**     
1-3 4 (14.28) 6 (24.00) 10 (18.87) 
4-5 5 (17.86) 0 (0.00) 5 (9.43) 
6+ 19 (67.86) 19 (76.00) 38 (71.70) 
Mean comparisons by ANOVA, categorical by chi-square    
*p<.05 
**p<.09 
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Table 4. Negative affect at baseline and during observation. 
 
  
Caucasian 
African 
American 
Total 
(n=27, 50.98%) (n=26, 49.02%) (n=53) 
 
mean (SD) mean (SD) mean (SD) 
Baseline visit questionnaires 
   Spielberger State Anxiety (20-80) 31.35 (10.64) 32.00 (9.17) 31.63 (9.92) 
Spielberger Trait Anxiety (20-80) 34.85 (10.20) 38.30 (7.91) 36.45 (9.34) 
Anxiety Sensitivity Score (0-72) 17.78 (8.60) 20.77 (12.54) 19.25 (10.72) 
CES-D  (0-60, clinical cut-off: 16) 12.24 (9.31) 14.88 (7.95) 13.53 (8.68) 
 
n (%) n (%) n (%) 
CES-D (categorical)    
Above clinical cut-off (16+) 12 (44.40) 13 (50.00) 28 (52.80) 
Below clinical cut-off (<16) 15 (55.60) 13 (50.00) 25 (47.20) 
 
mean (SD) mean (SD) mean (SD) 
Electronic diaries    
PANAS negative affect scale (10-50) 11.49 (3.50) 12.75 (3.89) 12.10 (3.71) 
PANAS sadness subscale (5-25) 6.03 (3.00) 7.12 (3.09) 6.55 (3.06) 
PANAS positive affect subscale* (10-50) 22.21 (7.22) 27.29 (6.21) 24.70 (7.18) 
Gibson negative affect measure (3-15) 3.99 (.57) 4.62 (1.49) 4.30 (1.55) 
Mean comparisons by ANOVA, categorical by chi-square    
*p<.05 
**p<.09 
CES-D:  Center for Epidemiologic Studies Depression Scale 
PANAS:  Positive and Negative Affect Schedule 
Gibson negative affect measure:  Items “mood swings, sensitive, irritable, anxious, difficulty 
concentrating, forgetful, blue” to mirror Gibson, 2011    
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Table 5. Sleep parameters at baseline and during observation 
 
 
Caucasian 
African 
American 
Total 
(n=27, 50.98%) (n=26, 49.02%) (n=53) 
  mean (SD) mean (SD) mean (SD) 
Baseline visit questionnaires:  PSQI  
   Sleep duration* 6.66 (1.23) 5.79 (1.48) 6.23 (1.41) 
Sleep efficiency (%) 82.82 (14.25) 76.86 (32.53) 79.96 (24.71) 
Overall sleep quality (0-3)£ 1.26 (.66) 1.54 (.76) 1.40 (.72) 
Total score*  
(Cut-off for poor sleep:  >5) 6.96 (3.40) 9.36 (0.75) 8.06 (3.63) 
 n (%) n (%) n (%) 
Have a bed partner*    
Yes 17 (63.00) 8 (30.80) 25 (47.20) 
No 10 (37.00) 18 (69.20) 28 (52.80) 
Sleep duration*    
7+ hours 16 (59.30) 7 (26.90) 23 (43.40) 
<7 hours 11 (40.70) 19 (73.10) 30 (56.60) 
Overall sleep quality    
Best/good) 19 (70.40) 14 (53.80) 33 (62.30) 
Fair/poor 8 (29.60) 12 (46.20) 20 (37.70) 
Total score**    
Good sleep quality (≤5) 11 (40.70) 4 (15.40) 15 (28.30) 
Poor sleep quality (>5) 16 (59.30) 22 (84.60) 38 (71.70) 
 mean (SD) mean (SD) mean (SD) 
Actigraphy     
Sleep duration (hours)* 6.02 (.91) 5.21 (.92) 5.63 (.98) 
Sleep efficiency (%)* 80.23 (7.40) 71.18 (13.09) 75.95 (11.24) 
Minutes of wake after sleep onset* 53.18 (21.50) 74.67 (45.67) 63.57 (36.10) 
 mean (SD) mean (SD) mean (SD) 
Electronic diaries    
 “Feel rested this morning?”  (1-6) 3.85 (.86) 4.01 (1.01) 3.93 (.93) 
 “Good night’s sleep?”  (1-6) 3.75 (.80) 3.74 (1.04) 3.75 (.92) 
Number of naps/day during 
observation .45 (.60) .53 (1.02) .49 (.82) 
Total number of naps during week  2.59 (3.00) 2.52 (2.77) 2.56 (2.89) 
Mean comparisons by ANOVA, categorical by chi-square    
*p<.05 
**p<.09 
£ Scores range from 0 (best) to 3 (worst) 
PSQI:  Pittsburgh Sleep Quality Index  
 74 
Table 6. Cortisol values over the observed period 
  
Caucasian 
African 
American 
Total 
(n=27, 50.98%) (n=26, 49.02%) (n=53) 
 
mean (SD) mean (SD) mean (SD) 
Salivary cortisol 
   Morning values (nmol/l) 17.62 (7.56) 15.72 (7.47) 16.82 (7.50) 
Bedtime values (nmol/l)* 2.64 (2.55) 5.75 (4.93) 3.96 (4.00) 
Diurnal slope** -1.16 (.74) -.70 (.80) -.97 (.79) 
Daily cortisol exposure (nmol/l)  10.19 (4.30) 10.84 (4.80) 10.46 (4.46) 
Hair cortisol    
Three month value (nmol/l) 2.50 (5.43) 5.41 (5.59) 3.50 (5.58)* 
Daily exposure    
Daily morning + bedtime average (nmol/l) 10.19 (4.30) 10.84 (4.80) 10.46 (4.46) 
Mean comparisons by ANOVA 
 
Though non-transformed means shown in this table, analyses were conducted using log-transformed 
values of both salivary and hair cortisol.  Diurnal slope calculated from log-transformed salivary cortisol 
values (nmol/l), adjusted by self-reported time between bedtime and morning collection. 
 
Morning and bedtime values calculated from all tubes labeled morning or bedtime, regardless of study 
day.  Diurnal slope and overall daily cortisol exposure calculated only from tubes labeled morning and 
bedtime on three consecutive days.  All calculations exclude original (non-logged) values <.3 nmol/l, >60 
nmol/l, and samples unlabeled as to time of collection. 
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Table 7. Specific Aim 1A:  Vasomotor Symptoms and Same Day Negative Affect 
 PANAS Negative Affect† PANAS Sadness Gibson Negative Affect£ 
 B, p-value B, p-value B, p-value 
Vasomotor 
Symptom Bother 
1.46, <0.001 0.46, 0.04 0.44, <0.01 
Daytime Hot Flash 
Bother 
1.46, <0.001 0.46, 0.04 0.44, <0.01 
Analyses conducted by multilevel hierarchical linear regression, using HLM 7.1 software.  
 
†Exploratory moderation analyses suggest that these relationships are strongest among African American 
participants (trend for frequency*race, interaction for bother*race p<.01). 
£Exploratory moderation analyses suggest that the relationship between vasomotor symptom bother and 
negative affect is strongest among African American participants (interaction for vasomotor symptom and 
daily hot flash bother*race p=.04). 
 
Model adjusted by age, menopausal status, race/ethnicity, body mass index, educational attainment, self-
rated health, time of day of diary reporting, and diary-reported health behaviors (exercise, caffeine intake, 
alcohol use, cigarette use), selected a priori.  Only those predictors significantly associated with the 
outcome (p<.05) in both unadjusted and fully adjusted models shown.   
 
Same day negative affect measured by Positive and Negative Affect Schedule:  Negative Affect Subscale; 
Positive and Negative Affect Schedule:  Sadness Subscale; Gibson Negative Affect (items “mood swings, 
sensitive, irritable, anxious, difficulty concentrating, forgetful, blue” to mirror Gibson, 2011).   
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Table 8. Specific Aim 1B:  Vasomotor Symptoms and Next Day Negative Affect 
 PANAS Negative Affect€ Gibson Negative Affect 
 B, p-value B, p-value 
Hot Flash Frequency 
(previous day) 
0.18, 0.046  
Night Sweat Severity 
(previous night) 
0.80, 0.02 0.62, <0.01 
Night Sweat Bother 
(previous night) 
0.61, 0.02 0.35, 0.03 
Analyses conducted by multilevel hierarchical linear regression, using HLM 7.1 software.  
 
Model adjusted by age, menopausal status, race/ethnicity, body mass index, educational attainment, self-
rated health, time of day of diary reporting, and diary-reported health behaviors (exercise, caffeine intake, 
alcohol use, cigarette use), selected a priori.  Only those predictors significantly associated with the 
outcome (p<.05) in both unadjusted and fully adjusted models shown.   
 
Same day negative affect measured by Positive and Negative Affect Schedule:  Negative Affect Subscale; 
Gibson Negative Affect (items “mood swings, sensitive, irritable, anxious, difficulty concentrating, 
forgetful, blue” to mirror Gibson, 2011).   
 
€When next day hot flash frequency is entered as the outcome in an otherwise equivalent model, no 
relationship is seen between previous day negative affect and next day hot flash frequency (B=0.01, 
p=0.33). 
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Table 9. Specific Aim 2:  Role of Sleep Parameters in Relationship between Vasomotor Symptoms and Next Day 
Negative Affect 
 PANAS Negative Affect Gibson Negative Affect 
 
No sleep 
in model 
Sleep 
duration 
in model 
Sleep 
efficiency 
in model 
WASO 
in 
model 
No 
sleep 
in 
model 
Sleep 
duration 
in model 
Sleep 
efficiency 
in model 
WASO in 
model 
 
B, p-
value 
B, p-
value 
B, p-
value 
B, p-
value 
B, p-
value 
B, p-
value 
B, p-
value 
B, p-
value 
Night 
sweat 
severity  
.78, 0.01 .86, 0.01 .82, 0.02 
 
.85, 
0.01 
.48, 
<.01 
.51, <.01 .48, <.01 .53, <.01 
Night 
sweat 
bother  
    
.29, 
0.03 
.30, 0.03 .29, 0.04 .32, .02 
 
Analyses conducted by multilevel hierarchical linear regression, using HLM 7.1 software.   
 
Model adjusted by age, menopausal status, race/ethnicity, body mass index, educational attainment, self-
rated health, time of day of diary reporting, and diary-reported health behaviors (exercise, caffeine intake, 
alcohol use, cigarette use), selected a priori.  Only those predictors significantly associated with the 
outcome (p<.05) in both unadjusted and fully adjusted models shown.   
 
Same day negative affect measured by Positive and Negative Affect Schedule:  Negative Affect Subscale; 
Positive and Negative Affect Schedule:  Sadness Subscale; Gibson Negative Affect (items “mood swings, 
sensitive, irritable, anxious, difficulty concentrating, forgetful, blue” to mirror Gibson, 2011).   
 
No other sleep variables exhibited significant associations with the measures of daily negative affect in 
base models, and so were not further analyzed in fully adjusted or mediational models. 
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Table 10. Specific Aim 3a:  Relationship between Cortisol and Negative Affect 
 
PANAS Negative Affect PANAS Sadness 
B, p-value B, p-value 
Cortisol slope .68, .01 .43, <.001 
Mean daily cortisol  0.07, 0.03 
Analyses conducted by multilevel hierarchical linear regression, using HLM 7.1 software.   
 
Model adjusted by age, menopausal status, race/ethnicity, body mass index, educational attainment, self-
rated health, time of day of diary reporting, and diary-reported health behaviors (exercise, caffeine intake, 
alcohol use, cigarette use), selected a priori.  Only those predictors significantly associated with the 
outcome (p<.05) in both unadjusted and fully adjusted models shown.   
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Table 11. Specific Aim 3a:  Relationship between Cortisol and Vasomotor Symptoms 
 
Vasomotor 
Symptom 
Severity 
Daytime Hot Flash 
Frequency 
Daytime Hot Flash 
Severity† 
Daytime Hot 
Flash Bother 
B, p-value B, p-value B, p-value B, p-value 
Cortisol slope .06, 0.02  .09, 0.03 .10, <.01 
Hair cortisol  0.05, 0.01   
Cortisol slope analyses conducted by multilevel hierarchical linear regression, using HLM 7.1 software; 
hair cortisol analyses conducted by linear regression, using SPSS 20.0 software.   
 
†Exploratory moderation analyses by race/ethnicity suggest that the relationship between a flatter cortisol 
slope and daytime hot flash severity may be stronger among the African American participants 
(interaction B .11,  p=.09, non-significant trend).  No other differences in relationships by race/ethnicity 
were seen. 
 
Model adjusted by age, menopausal status, race/ethnicity, body mass index, educational attainment, self-
rated health, time of day of diary reporting, and diary-reported health behaviors (exercise, caffeine intake, 
alcohol use, cigarette use), selected a priori.  Only those predictors significantly associated with the 
outcome (p<.07) in both unadjusted and fully adjusted models shown.   
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Table 12. Specific Aim 3a:  Relationship between Cortisol and Sleep Parameters 
 
Sleep Duration 
(previous night) 
Sleep Efficiency 
(previous night) 
WASO 
(previous night) 
Sleep Duration 
(following night) 
B, p-value B, p-value  B, p-value 
Cortisol 
slope 
-.38, <.01  -7.62, 0.02 .49, 0.04 
Mean daily 
cortisol 
 -.004, 0.03 2.68, 0.02  
Analyses conducted by multilevel hierarchical linear regression, using HLM 7.1 software.   
 
Model adjusted by age, menopausal status, race/ethnicity, body mass index, educational attainment, self-
rated health, time of day of diary reporting, and diary-reported health behaviors (exercise, caffeine intake, 
alcohol use, cigarette use), selected a priori.  Only those predictors significantly associated with the 
outcome (p<.05) in both unadjusted and fully adjusted models shown.   
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Table 13. Specific Aim 3b:  Diurnal Cortisol Slope as a Mediator Linking Vasomotor Symptoms with Negative 
Affect 
 
PANAS Negative Affect Gibson Negative Affect 
No cortisol  Cortisol in model No cortisol  Cortisol in model 
B, p-value B, p-value B, p-value B, p-value 
Daytime hot flash frequency   -.31, 0.04 -.33, .045 
Daytime hot flash severity ± 2.28, <.01 2.16, <.01 0.83, <.01 0.61, .048 
Daytime hot flash bother π 1.73, <.01 1.75, <.01 .49, 0.04 .28, 0.17 
Analyses conducted by multilevel hierarchical linear regression, using HLM 7.1 software. 
 
Model adjusted by age, menopausal status, race/ethnicity, body mass index, educational attainment, self-
rated health, time of day of diary reporting, and diary-reported health behaviors (exercise, caffeine intake, 
alcohol use, cigarette use), selected a priori.  Only those predictors significantly associated with the 
outcome (p<.05) in both unadjusted and fully adjusted models shown.   
 
±When cortisol slope replaced with mean daily cortisol exposure in otherwise equivalent models, B=0.10, 
p=0.08 (PANAS NA), B=0.02, p=0.13 (Gibson NA).   
 
πWhen cortisol slope replaced with mean daily cortisol exposure in otherwise equivalent models, B=0.10, 
p=0.08 (PANAS NA), B=0.02, p=0.15 (Gibson NA).   
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Table 14. Correlation Matrix of Key Variables:  Negative Affect 
Negative Affect 
 PANAS Negative 
Affect 
(n=53) 
PANAS Sadness 
(n=53) 
Gibson Negative Affect 
(n=53) 
Covariates    
Age (n=53) -.33* -.24 -.29* 
BMI (n=53) .09 .17 .07 
Menopausal status (n=53) -.24 -.27 -.25 
Race/ethnicity (n=53) .17 .17 .20 
Education (n=53) -.31* -.26 -.36* 
Self-rated health (n=53) -.16 -.24 -.24 
Report exercise in diary 
(n=39) 
.31 .20 .25 
Report caffeine intake in 
diary (n=39) 
.24 .24 .15 
Report alcohol use in 
diary(n=39) 
.12 .06 .23 
Report cigarette use in diary 
(n=39) 
.53* .50* .53* 
Predictor Variables    
Vasomotor Symptom 
Frequency (n=53) 
.23 .08 .10 
Vasomotor Symptom 
Severity (n=53) 
.36* .21 .31* 
Vasomotor Symptom 
Bother (n=53) 
.34* .21 .25 
Diurnal Cortisol Slope 
(n=44) 
-.23 -.11 -.17 
Overall Mean Daily 
Cortisol Exposure (n=44) 
-.36* -.43* -.24 
Hair Cortisol (n=35) .16 .26 .12 
Sleep Duration (n=52) -.04 -.14 -.16 
Sleep Efficiency (n=52) -.21 -.26 -.31* 
Sleep After Wake Onset 
(n=52) 
.19 .21 .23 
*p<.05 
Referents in categorical variables:  Race/ethnicity:  Caucasian; Menopausal status:  Perimenopausal; 
Education:  High school or less; Self-rated health:  Fair/poor; Health behaviors (exercise, caffeine, 
alcohol, cigarettes):  No reported use over observed period; Vasomotor Symptom Severity:  Mild; 
Vasomotor Symptom Bother:  Not at all. 
 83 
Table 15. Correlation Matrix of Key Variables:  Vasomotor Symptoms 
Vasomotor Symptoms 
 Vasomotor 
Symptom 
Frequency 
(n=53) 
Vasomotor Symptom 
Severity 
(n=53) 
Vasomotor Symptom 
Bother 
(n=53) 
Covariates    
Age (n=53) -.19 -.06 .02 
BMI (n=53) .14 .34* .27* 
Menopausal status (n=53) -.17 -.04 -.03 
Race/ethnicity (n=53) .20 .16 .09 
Education (n=53) -.18 -.13 -.08 
Self-rated health (n=53) -.14 -.20 -.17 
Report exercise in diary 
(n=39) 
.25 -.05 .00 
Report caffeine intake in 
diary (n=39) 
-.21 .08 .06 
Report alcohol use in diary 
(n=39) 
.07 -.03 -.08 
Report cigarette use in diary 
(n=39) 
.22 .03 .02 
Predictor Variables    
Diurnal Cortisol Slope 
(n=44) 
.09 .06 .01 
Overall Mean Daily Cortisol 
Exposure (n=44) 
.03 -.05 -.01 
Hair Cortisol (n=35) .36
*
 .11 .00 
Sleep Duration (n=52) .12 -.04 -.07 
Sleep Efficiency (n=52) -.10 -.29
*
 -.23 
Sleep After Wake Onset 
(n=52) 
.26* .21 .16 
PANAS Negative Affect 
(n=53) 
.23 .36* .34* 
PANAS Sadness (n=53) .08 .21 .21 
Gibson Negative Affect 
(n=53) 
.10 .31* .25 
*p<.05 
Referents in categorical variables:  Race/ethnicity:  Caucasian; Menopausal status:  Perimenopausal; 
Education:  High school or less; Self-rated health:  Fair/poor; Health behaviors (exercise, caffeine, 
alcohol, cigarettes):  No reported use over observed period; Vasomotor Symptom Severity:  Mild; 
Vasomotor Symptom Bother:  Not at all.
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Table 16. Correlation Matrix of Key Variables:  Cortisol 
Cortisol 
 Diurnal Cortisol Slope 
(n=44) 
Overall Mean Daily 
Cortisol Exposure 
(n=44) 
Hair Cortisol 
(n=39) 
Covariates    
Age (n=53) .02 .11 -.06 
BMI (n=53) .20 -.14 .24 
Menopausal status (n=53) .17 .09 -.32 
Race/ethnicity (n=53) -.01 .07 .45* 
Education (n=53) -.33* .00 -.20 
Self-rated health (n=53) -.20 -.07 -.19 
Report exercise in diary (n=39) .16 -.30 .26 
Report caffeine intake in diary (n=39) -.27 .05 .06 
Report alcohol use in diary (n=39) -.01 -.19 -.23 
Report cigarette use in diary (n=39) .08 -.12 .47* 
Predictor Variables    
Sleep Duration (n=52) -.12 .14 .30 
Sleep Efficiency (n=52) -.01 -.01 -.35* 
Sleep After Wake Onset (n=52) .11 .22 .57* 
PANAS Negative Affect (n=53) -.23 -.36
*
 .16 
PANAS Sadness (n=53) -.11 -.43
*
 .26 
Gibson Negative Affect (n=53) -.17 -.24 .12 
VMS Frequency (n=53) -.10 .03 .36
*
 
VMS Severity (n=53) .06 -.05 .11 
VMS Bother (n=53) .01 -.01 .00 
 *p<.05 
 
Referents in categorical variables:  Race/ethnicity:  Caucasian; Menopausal status:  Perimenopausal; 
Education:  High school or less; Self-rated health:  Fair/poor; Health behaviors (exercise, caffeine, 
alcohol, cigarettes):  No reported use over observed period; Vasomotor Symptom Severity:  Mild; 
Vasomotor Symptom Bother:  Not at all. 
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Table 17. Correlation Matrix of Key Variables:  Sleep 
Sleep 
 Sleep Duration 
(n=52) 
Sleep Efficiency 
(n=52) 
Wake After Sleep 
Onset 
(n=52) 
Age (n=53) -.25 .06 -.12 
BMI (n=53) -.16 -.16 .15 
Menopausal status 
(n=53) 
-.20 .14 -.20 
Race/ethnicity (n=53) -.06 -.30* .32* 
Education (n=53) .12 .25 -.10 
Self-rated health (n=53) -.08 .38* -.50* 
Report exercise in diary 
(n=39) 
-.12 -.36* .42* 
Report caffeine intake 
in diary (n=39) 
-.12 .04 -.17 
Report alcohol use in 
diary (n=39) 
-.11 .03 .03 
Report cigarette use in 
diary (n=39) 
-.12 -.03 -.15 
Predictor Variables    
PANAS Negative 
Affect (n=53) 
-.04 -.21 .19 
PANAS Sadness (n=53) -.14 -.26 .21 
Gibson Negative Affect 
(n=53) 
-.16 -.31
*
 .23 
VMS Frequency (n=53) .12 -.10 .26 
VMS Severity (n=53) -.14 -.26 .32* 
VMS Bother (n=53) -.07 -.18 .28* 
Diurnal Cortisol Slope 
(n=44) 
-.18 .16 .04 
Overall Mean Daily 
Cortisol Exposure 
(n=44) 
.14 -.01 .22 
Hair Cortisol (n=35) .30 -.35
*
 .57
*
 
*p<.05 
Referents in categorical variables:  Race/ethnicity:  Caucasian; Menopausal status:  Perimenopausal; 
Education:  High school or less; Self-rated health:  Fair/poor; Health behaviors (exercise, caffeine, 
alcohol, cigarettes):  No reported use over observed period; Vasomotor Symptom Severity:  Mild; 
Vasomotor Symptom Bother:  Not at all. 
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APPENDIX A 
KEY VARIABLE CATEGORIES FOR STATISTICAL ANALYSIS 
VMS:  Occurrence (yes/no), frequency (number), rate (number reported within observation 
period, based on diary timestamps), severity (mild:  sensation of heat without sweating; 
moderate:  sensation of heat with sweating, able to continue activity; severe:  sensation of heat 
with sweating, causing cessation of activity), and bother (not at all, very little, moderately, a lot). 
NS:  Night sweats, reported in morning diaries and with event marker button press overnight. 
Negative affect:  PANAS negative affect scale, positive affect scale, sadness subscale; negative 
affect measure comparable to Gibson et al. (Gibson et al., 2011).  
Sleep:  Actigraphy-derived sleep duration, sleep efficiency, and wake after sleep onset. 
Cortisol:  Diurnal slope calculated from awakening value subtracted from bedtime value, 
adjusted by day length; cortisol exposure calculated as the average of the morning and bedtime 
value for each participant, each day; and an overall value assessed from hair samples. 
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APPENDIX B 
STATISTICAL ANALYSIS EQUATIONS 
 
B.1 SPECIFIC AIM 1 
Specific Aim 1: Examine the contribution of VMS to within-day and next-day negative 
affect. 
 Using three-level hierarchical linear models, within day analyses were conducted with 
observations (level 1) nested with days (level 2), nested within participants (level 3), negative 
affect was regressed on VMS from the same day (1) and the previous day (2).  Additionally, 
negative affect was regressed on night sweats from the previous night reporting in morning 
diaries (3).   
Equations: 
1) Negative affectijk= γ000 + γ100VMSijk* + r0 + u00 + e 
2) Negative affectijk = γ000 + γ100lagVMSijk*+ r0 + u00 + e 
3) Negative affectijk = γ000 + γ010NSjk* + r0 + u00 + e 
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Variables:  
Negative affectijk:  Negative affect of observation i in day j of participant k  
γ000:  Negative affect grand mean 
γ100VMSijk:  Main effect of same-day VMS on negative affect 
γ100lagVMSijk:  Main effect of previous day VMS on negative affect 
γ010NSijk:  Main effect of previous night’s night sweats on negative affect 
r0:  Random day effect (deviation of day j’s mean from the participant mean) 
u00:  Random participant effect (deviation of participant k’s mean from the grand mean) 
e:  Random observation effect (deviation of observation ijk’s value from the day mean)  
B.2 SPECIFIC AIM 2 
 
Specific Aim 2:  Examine sleep as a mediator of the association between VMS and next-day 
negative affect. 
 In order to test mediation in multilevel models, variables in the mediational chain may 
affect a variable at the same or lower levels, but not higher levels (Kenny, Korchmaros, & 
Bolger, 2003).  As VMS and negative affect are measured at level 1 (multiple timepoints within 
a day), and sleep is measured at level 2 (one variable for each sleep parameter per day), it was 
necessary to aggregate VMS and negative affect within participants, within each day.  Mediation 
was then tested with two-level hierarchical models using the Krull-MacKinnon method (Krull & 
MacKinnon, 1999), with mean daily observations (level 1) nested within women (level 2) to 
assess observations within women.  In the first step (1), negative affect was predicted from 
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previous day VMS with two-level hierarchical linear regression.  In the second step (2), sleep 
from the night prior to the negative affect measurement was included in the regression model in 
order to estimate negative affect from both VMS and sleep (A).  The difference between the 
estimates of the VMS variable in the first and second equation estimated the extent to which 
sleep accounts for the relationship between VMS and next day negative affect.  Analyses were 
repeated with self-reported nocturnal VMS from morning diaries from the same day that 
negative affect was reported in place of previous day VMS (B).     
Equations: 
A) 
1) Negative affectjk = ζ00 + ζ10lagVMSjk*+ r0 + r1lagVMSjk + e 
2) Negative affectjk = ζ00 + ζ10lagVMSjk + ζ20sleepjk* +  r0 + r1lagVMSjk + r2sleepjk + e 
B) 
1) Negative affectjk = ζ00 + ζ10NSjk + r0 + r1NSjk + e 
2) Negative affectjk = ζ00 + ζ10NSjk + ζ20sleepjk* +  r0 + r1NSjk + r2sleepjk + e 
Variables:  
Negative affectjk:  Aggregate negative affect from day j of participant k  
ζ00:  Negative affect grand mean 
ζ10lagVMSjk:  Main effect of aggregate previous day VMS on aggregate negative affect 
 ζ20sleepjk:  Main effect of previous night’s sleep on aggregate negative affect 
r0:  Random participant effect (deviation of participant k’s mean from the grand mean) 
r1lagVMSjk:  Random VMS effect 
r1NSjk:  Random night sweats effect 
r2sleepjk:  Random sleep effect 
e:  Random day effect (deviation of day j’s mean from the participant mean)  
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B.3 SPECIFIC AIM 3A 
 
Specific Aim 3a:  Examine diurnal cortisol slope and hair cortisol as physiologic measures 
associated with VMS, sleep parameters, and negative affect 
 Cortisol, sleep, VMS, and negative affect data were collected at different levels, with 
salivary cortisol collected on only 3 of the 7 days comprising level 2 and hair cortisol measured 
from a single sample to assess overall (past three month) exposure.  As HLM is not robust to 
missing data for primary predictors at level 2 in either 2 or 3 levels models, this altered the 
appropriate analytic approaches to testing associations, and limited ability to examine temporal 
relations between these factors over the observed period.  These relationships were therefore 
examined in several ways, with one and two level data structure categorization.  For diurnal 
cortisol, analysis of all variables was first restricted to the three days of cortisol collection (A), 
and aggregate measures resulting in one value for each variable per participant over the observed 
period (B).  The latter was repeated with hair cortisol values in place of the aggregate mean 
diurnal slope value.  The limitations of these approaches is acknowledged, as the restricted range 
of observations will reduce reliability and power, and aggregate measures may cloud inter- and 
intraindividual differences in key measures.  
A) 1.   Using two-level hierarchical linear modeling restricted to the three days of cortisol  
collection, diurnal cortisol slope at level 2 was separately modeled as a function of      
VMS (a), negative affect (b), and sleep parameters (c) from the night preceding and 
following sampling.   
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B)  1.  Using linear regression models, aggregate measures of all observations per participant 
of VMS, diurnal cortisol slope, and sleep were examined.  Diurnal cortisol slope was 
modeled separately as a function of VMS (a), negative affect (b), and sleep (c).   
2.  This same analysis will be repeated with the single overall cortisol measure from hair  
 sampling, such that hair cortisol values were modeled separately as a function of VMS  
 (a), negative affect (b), and sleep (c).   
Equations: 
A1a)  Cortisoljk = ζ00 + ζ10VMSjk* + r0 + e 
A2b)  Cortisoljk = ζ00 + ζ10NAjk* + r0 + e 
A2c)  Cortisoljk = ζ00 + ζ10sleepjk* + r0 + e 
B1/2a)  Cortisol = 0 + 1VMS* + e 
B1/2b)  Cortisol = 0 + 1negative affect* + e 
B1/2c)  Cortisol = 0 + 1sleep* + e 
Variables: 
A1) 
Cortisoljk:  Diurnal cortisol slope from day j of participant k 
ζ00:  Diurnal cortisol slope grand mean 
ζ10VMSjk:  Main effect of VMS on diurnal cortisol slope 
ζ10NAjk:  Main effect of negative affect on diurnal cortisol slope 
ζ10sleepjk:  Main effect of sleep on diurnal cortisol slope 
r0:  Random participant effect (deviation of participant k’s mean from the grand mean) 
e:  Random day effect (deviation of day j’s mean from the participant mean)  
B1) 
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Cortisol:  Mean diurnal cortisol slope 
0:  intercept 
1VMS:  Main effect of mean VMS on diurnal cortisol slope 
1NS:  Main effect of mean night sweats on diurnal cortisol slope 
1negative affect:  Main effect of mean negative affect on diurnal cortisol slope 
1sleep:  Main effect of mean sleep on diurnal cortisol slope 
e:  error term 
B2) 
Cortisol:  Hair cortisol value 
0:  intercept 
1VMS:  Main effect of mean VMS on hair cortisol value 
1NS:  Main effect of mean night sweats on hair cortisol value 
1negative affect:  Main effect of mean negative affect on hair cortisol value 
1sleep:  Main effect of mean sleep on hair cortisol value 
e:  error term 
B.4 SPECIFIC AIM 3B 
 
Specific Aim 3b: Examine diurnal cortisol as a mediator linking VMS with negative affect. 
 In order to test mediation in multilevel models, variables in the mediational chain may 
affect a variable at the same or lower levels, but not higher levels.  Mediation was tested with 
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two-level hierarchical models using the Krull-MacKinnon method (Krull & MacKinnon, 1999) 
with data from the three days of cortisol collection (A), and with simple linear regression using 
the Sobel method (Sobel, 1982) with mean aggregate values of all parameters over the observed 
period (B).   
A) In the first step (1), negative affect was predicted from VMS with two-level hierarchical 
linear regression.  In the second step (2), diurnal cortisol slope was included in the 
regression model in order to estimate negative affect from both VMS and diurnal cortisol.  
The difference between the estimates of the negative affect slope variable in the first and 
second equation estimate the extent to which diurnal cortisol slope accounts for the 
relationship between VMS and negative affect. 
B)  In the first step (1), mean negative affect was predicted from mean VMS and mean 
diurnal cortisol slope with linear regression.  In the second step (2), diurnal cortisol slope was 
predicted from mean VMS.  The Sobel product of coefficients was calculated by multiplying 
the partial regression effect for diurnal cortisol slope predicting negative affect by the simple 
coefficient for VMS predicting diurnal cortisol slope (3).  Bootstrapping methods were used 
to test for significance. 
Equations: 
A) 
1.  Negative affectjk = ζ00 + ζ10VMSjk* + r0 + r1VMSjk + e 
2.  Negative affectjk = ζ00 + ζ10VMSjk + ζ20cortisoljk* +  r0 + r1VMSjk + r2cortisoljk + e 
B)  
1.  Negative affect = B0 + B1VMS + B2cortisol + e 
2.  Cortisol = B0 +BVMS + e 
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3.  Bindirect* = (B2cortisol)(BVMS) 
Variables:  
A) 
Negative affectjk:  Mean negative affect from day j of participant k  
ζ00:  Negative affect grand mean 
ζ10VMSjk:  Main effect of mean VMS from day j of participant k on negative affect 
 ζ20cortisoljk:  Main effect of diurnal cortisol slope from day j of participant k on negative affect 
r0:  Random participant effect (deviation of participant k’s mean from the grand mean) 
r1VMSjk:  Random VMS effect 
r1cortisoljk:  Random cortisol effect 
e:  Random day effect (deviation of day j’s mean from the participant mean)  
B) 
Negative affect = Negative affect dependent variable 
Cortisol = Diurnal cortisol slope dependent variable 
 B0 = Dependent variable intercept 
B1VMS = Main effect of VMS on negative affect, controlling for diurnal cortisol slope 
B2cortisol  = Main effect of diurnal cortisol slope on negative affect, controlling for VMS 
BVMS = Main effect of VMS on diurnal cortisol slope 
Bindirect = Indirect effect of diurnal cortisol slope on negative affect 
e = error term 
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APPENDIX C 
ELECTRONIC DIARY TEMPLATES 
Sample signaled-entry diary (each item appears on an individual screen; participants had verbal and 
written instructions about the scales utilized): 
Since last entry,  
How MANY hot flashes? 
(Drop-down menu for #) 
0, 1, … 5+ 
………………………………………………….. 
What TIME last hot flash? 
________________ 
………………………………………………….. 
How SEVERE were they? 
0/none  1/mild  2/moderate 3 /severe 
…………………………………………………… 
How BOTHERSOME were they? 
0/none  1/not at all 2/very little  3/moderately   4/a lot  
…………………………………………………… 
How IRRITABLE do you feel right now? 
1 2 3 4 5 
(same format repeated for all individual mood items) 
…………………………………………………… 
Are you alone? 
Y N 
 96 
…………………………………………………… 
Where are you? 
1/at work 2/at home 3/in public 
 
Sample self-initiated morning diary: 
 
Time got into bed? 
________________ 
AM PM 
………………………………………………….. 
Time tried to go to sleep? 
________________ 
AM PM 
………………………………………………….. 
Time woke up? 
________________ 
AM PM 
………………………………………………….. 
Any trouble sleeping? 
NO YES 
………………………………………………….. 
This morning I feel rested: 
NO!   NO    no  yes YES YES! 
………………………………………………….. 
My sleep last night was very good: 
NO!   NO    no  yes YES YES! 
………………………………………………….. 
Overnight, how many hot flashes/since you went to bed? 
_______________ 
………………………………………………….. 
What TIME last hot flash? 
________________ 
AM PM 
………………………………………………….. 
How SEVERE were they? 
0/none  1/mild  2/moderate 3 /severe 
…………………………………………………… 
How BOTHERSOME were they? 
0/none  1/not at all 2/very little  3/moderately   4/a lot  
…………………………………………………… 
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Sample self-initiated bedtime diary: 
Since last entry,  
How MANY hot flashes? 
_______________ 
………………………………………………….. 
How SEVERE were they? 
0/none  1/mild  2/moderate 3 /severe 
…………………………………………………… 
How BOTHERSOME were they? 
0/none  1/not at all 2/very little  3/moderately   4/a lot  
…………………………………………………… 
How IRRITABLE do you feel right now? 
1 2 3 4 5 
(same format repeated for all individual mood items) 
…………………………………………………… 
Did you EXERCISE today? 
NO YES 
(If yes): 
Last time today? 
MORNING AFTERNOON      EVENING 
…………………………………………………… 
Did you have CAFFEINE today? 
NO YES 
(If yes): 
Last time today? 
MORNING AFTERNOON      EVENING 
…………………………………………………… 
Did you drink ALCOHOL today? 
NO YES 
(If yes): 
Last time today? 
MORNING AFTERNOON      EVENING 
…………………………………………………… 
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Did you smoke CIGARETTES today? 
NO YES 
(If yes): 
Last time today? 
MORNING AFTERNOON      EVENING 
………………………………………………… 
Did you sleep during the daytime today? 
NO YES 
(If yes):  How MANY times did you take a nap today? 
_________________ 
Nap times: 
From ______ AM/PM to ______ AM/PM 
From ______ AM/PM to ______ AM/PM 
From ______ AM/PM to ______ AM/PM 
From ______ AM/PM to ______ AM/PM 
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